Submission Request History

Navbar

Guidelines
Compendia & Templates
Education & Research
Patient Resources
Business & Policy
Global

Guidelines COVID-19 Resources Treatment by Cancer Type Detection, Prevention, and Risk Reduction Supportive Care Specific Populations Guidelines for Patients Guidelines With Evidence Blocks NCCN Framework For Resource Stratification Harmonized Guidelines International Adaptations and Translations NCCN Mobile Apps Guidelines Process Guidelines Panels and Disclosure Permission to Cite or Use NCCN Content Recently Updated Guidelines Submission Request to the Guidelines Panels Check Back Soon to Order Free Print Copies

Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Ampullary Adenocarcinoma Anal Carcinoma Basal Cell Skin Cancer B-Cell Lymphomas Biliary Tract Cancers Bladder Cancer Bone Cancer Breast Cancer Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid Leukemia Colon Cancer Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers Gastric Cancer Gastrointestinal Stromal Tumors Gestational Trophoblastic Neoplasia Hairy Cell Leukemia Head and Neck Cancers

Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Melanoma: Cutaneous Melanoma: Uveal Merkel Cell Carcinoma Mesothelioma: Peritoneal Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Fusion Genes Myeloproliferative Neoplasms Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Pancreatic Adenocarcinoma Pediatric Acute Lymphoblastic Leukemia Pediatric Aggressive Mature B-Cell Lymphomas

Pediatric Central Nervous System Cancers Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Systemic Light Chain Amyloidosis Systemic Mastocytosis T-Cell Lymphomas Testicular Cancer Thymomas and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vulvar Cancer Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Wilms Tumor (Nephroblastoma)

Breast Cancer Risk Reduction Breast Cancer Screening and Diagnosis Colorectal Cancer Screening

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Genetic/Familial High-Risk Assessment: Colorectal Lung Cancer Screening

Prostate Cancer Early Detection

Adult Cancer Pain Antiemesis Cancer-Associated Venous Thromboembolic Disease Cancer-Related Fatigue

Distress Management Hematopoietic Cell Transplantation Hematopoietic Growth Factors Management of Immunotherapy-Related Toxicities

Palliative Care Prevention and Treatment of Cancer-Related Infections Smoking Cessation Survivorship

Adolescent and Young Adult (AYA) Oncology

Cancer in People with HIV

Older Adult Oncology

Acute Lymphoblastic Leukemia (adult) Acute Lymphoblastic Leukemia (pediatric) Acute Myeloid Leukemia Adolescent and Young Adult Cancer Adrenal Tumors Anal Cancer Anemia and Neutropenia - Low Red and White Blood Cell Counts Basal Cell Skin Cancer B-Cell Lymphomas - Diffuse Large B-Cell Lymphomas B-Cell Lymphomas - Follicular Lymphoma B-Cell Lymphomas - Mantle Cell Lymphoma B-Cell Lymphomas - Marginal Zone Lymphoma Bladder Cancer Bone Cancer Brain Cancer - Gliomas Breast Cancer - DCIS Breast Cancer Breast Cancer - Invasive Breast Cancer Breast Cancer - Metastatic Breast Cancer Breast Cancer Screening and Diagnosis Central Nervous System Cancers - Primary Central Nervous System Lymphoma Cervical Cancer Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia Colon Cancer Colorectal Cancer Screening Distress Management - Distress During Cancer Care Esophageal Cancer Gallbladder and Bile Duct Cancers Graft-Versus-Host Disease Head and Neck Cancers - Nasopharyngeal Cancer Head and Neck Cancers - Oral Cancers Head and Neck Cancers - Oropharyngeal Cancer Hodgkin Lymphoma Immunotherapy Side Effects: CAR T-Cell Therapy Immunotherapy Side Effects: Immune Checkpoint Inhibitors Kidney Cancer Liver Cancer Lung Cancer Screening Melanoma Mesothelioma: Pleural - Malignant Pleural Mesothelioma Multiple Myeloma Mycosis Fungoides/Sézary Syndrome Myelodysplastic Syndromes Myeloproliferative Neoplasms

Nausea and Vomiting Neuroendocrine Tumors Non-Small Cell Lung Cancer - Early and Locally Advanced Non-Small Cell Lung Cancer - Metastatic Ovarian Cancer Pancreatic Cancer Peripheral T-Cell Lymphoma Primary Cutaneous Lymphomas Prostate Cancer: Advanced Stage Prostate Cancer: Early Stage Rectal Cancer Small Cell Lung Cancer Soft Tissue Sarcoma Squamous Cell Skin Cancer Stomach Cancer Survivorship Care for Cancer-Related Late and Long-Term Effects Survivorship Care for Healthy Living Systemic Mastocytosis Thyroid Cancer Uterine Cancer Waldenström Macroglobulinemia

About Clinical Practice Guidelines Development and Update of Guidelines

Transparency Process Guidelines Panels Meeting Schedule

Disclosure Policies and Potential Conflicts of Interest

Guidelines Panels

Guideline Steering Committee

Submission Request History

Compendia & Templates Compendia Chemotherapy Order Templates

NCCN Compendia Drugs and Biologics Compendium Biomarkers Compendium

Imaging AUC Compendium Radiation Therapy Compendium Subscribe to NCCN Compendium

Recognition Program

Browse by Cancer Type View Chemotherapy Order Templates User Guide

EHR Integration Chemotherapy Order Templates Committee

Subscribe to NCCN Templates Chemotherapy Order Templates Reviewer Acknowledgement

Education & Research Events and Programs Oncology Research Program JNCCN Publications

Continuing Education Calendar of Events 2023 Breast Cancer Congress

Annual Conference Annual Conference 2023 Exhibit Guide Exhibit Hall Floor Plan

Exhibit Show Services Nursing Events Annual Congress: Hematologic Malignancies

Oncology Research Program (ORP) Current Opportunities ORP Recent News ORP Grant History

Scientific Publications Clinical Trials Young Investigator Awards Informed Consent Language Database

Best Practices for Biorepositories Shared Resources Disclosure Policy

About JNCCN

Subscribe to JNCCN

JNCCN Email Updates

Business & Policy Business Policy and Advocacy Program

Corporate Council Academy Trends U.S. Surveys Trends Global Surveys Flash Updates

Check Back Soon to Order Free Pocket Guidelines and Patient Guidelines Support Opportunities Advertising Opportunities Research Tools: REMS Employer Resources

Virtual Reimbursement Resource Room and App Health Information Technology Licenses Embargo Policy Firewall Policy

Policy and Advocacy Program Oncology Policy Summits

Policy Priority: Improve and Facilitate Quality Cancer Care Policy Priority: Ensure Patient Accessibility

Policy Priority: Increase Use of Guidelines State Oncology Society Forum

Global Global Program Global Clinical Resources Global Support Opportunities Global Policy Contact NCCN Global NCCN Joins the Global Plea for Peace in Ukraine and Recognizes the Profound Impact to Cancer Care

Africa Asia Caribbean

Europe Latin America Middle East & North Africa

Worldwide

Clinical Guidelines Translations Guidelines for Patients Translations

Distress Thermometer Tool Translations International Adaptations

Framework for Resource Stratification Harmonized Guidelines

Global Corporate Council Global Academy

Trends Global Surveys eBulletin Global Edition

Home
Guidelines
Submission Request to the Guidelines Panels
Submission Request History

Submission Request History

COVID-19 Resources
Treatment by Cancer Type
Detection, Prevention, and Risk Reduction
Supportive Care
Specific Populations
Guidelines for Patients
Guidelines With Evidence Blocks
NCCN Framework For Resource Stratification
Harmonized Guidelines
International Adaptations and Translations
NCCN Mobile Apps
Guidelines Process
Guidelines Panels and Disclosure
Permission to Cite or Use NCCN Content
Recently Updated Guidelines
Submission Request to the Guidelines Panels
- Submission Request History
Check Back Soon to Order Free Print Copies

Acute Lymphoblastic Leukemia Panel

Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 03/29/2018
Hypercvad rituximab Submitted by Oregon Society of Medical Oncology on 08/08/2018
clonoSEQ® Submitted by Adaptive Biotechnologies on 09/13/2018
Glucarpidase Submitted by BTG International on 09/24/2018
clonoSEQ® Submitted by Adaptive Biotechnologies on 09/28/2018
Dasatinib Submitted by Bristol-Myers Squibb Company on 01/03/2019
Minimal (measurable) Residual Disease (MRD) Submitted by Adaptive Biotechnologies on 09/13/2019
clonoSEQ Submitted by Adaptive Biotechnologies on 10/27/2020
Blinatumomab Submitted by Amgen Inc. on 12/10/2020
blinatumomab Submitted by Amgen Inc. on 03/10/2021
Asparaginase erwinia chrysanthemi (recombinant) Submitted by Jazz Pharmaceuticals Inc. on 07/02/2021
Tecartus Submitted by Kite on 10/20/2021
MRD Submitted by Adaptive Biotechnologies on 10/22/2021
Ponatinib Submitted by Takeda Oncology on 10/28/2021
IV cetirizine Submitted by TerSera Therapeutics on 11/09/2021

Acute Myeloid Leukemia Panel

Gilteritinib Submitted by Astellas Pharma Inc. on 04/13/2018
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Submitted by Stemline Therapeutics, Inc. on 04/20/2018
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 04/23/2018
Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals Inc. on 04/27/2018
Venetoclax Submitted by AbbVie, Inc. on 07/12/2018
Cytarabine and Daunorubicin Submitted by Jazz Pharmaceuticals Inc. on 11/05/2018
Venetoclax Submitted by AbbVie, Inc. on 11/21/2018
Tagraxofusp Submitted by Stemline Therapeutics, Inc. on 12/13/2018
Gilteritinib Submitted by Astellas Pharma Inc. on 01/18/2019
Liposomal Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals Inc. on 03/07/2019
Daunorubicin and Cytarabine Submitted by Jazz Pharmaceuticals Inc. on 03/14/2019
Venetoclax Submitted by AbbVie, Inc. on 03/21/2019
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 04/02/2019
Quizartinib Submitted by Daiichi-Sankyo, Inc. on 04/19/2019
Gemtuzumab Ozogamicin Submitted by Pfizer Inc. on 04/22/2019
Tagraxofusp Submitted by Stemline Therapeutics, Inc. on 04/24/2019
Cytarabine and Daunorubicin Submitted by Jazz Pharmaceuticals Inc. on 04/26/2019
Gilterltinib Submitted by Astellas Pharma Inc. on 06/05/2019
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 05/01/2020
Venetoclax Submitted by AbbVie, Inc. on 06/26/2020
CC-486 Submitted by Bristol-Myers Squibb Company on 07/07/2020
Venetoclax + HMAs Submitted by AbbVie, Inc. on 08/14/2020
Azacitidine Submitted by Bristol-Myers Squibb Company on 09/01/2020
Venetoclax Submitted by Genentech, Inc. and AbbVie, Inc. on 01/25/2021
Sorafenib Submitted by Anticancer Fund on 04/07/2021

Adolescent and Young Adult Oncology Panel

Sodium Thiosulfate Submitted by Fennec Pharma on 12/02/2022

Adult Cancer Pain Panel

Interventional radiology Submitted by Society of Interventional Oncology on 09/16/2019
Polymerized Cross-linked Sucralfate Submitted by MMI Script Hub and Medical Supplies on 06/18/2020
Algorithm & Discussion Changes Submitted by Society of Interventional Oncology on 08/11/2020
Intravenous patient controlled analgesia Submitted by Fujian Cancer Hospital on 06/19/2022

Antiemesis Panel

Fosnetupitant and Palonosetron Submitted by Helsinn Healthcare SA on 05/18/2018
Lenvatinib Submitted by Eisai Inc. on 04/21/2020
Akynzeo Submitted by Helsinn Healthcare SA on 08/24/2021

B-Cell Lymphomas Panel

Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 05/02/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 06/03/2018
Next-generation sequencing Submitted by Adaptive Biotechnologies on 07/18/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 08/07/2018
Duvelisib Submitted by Verastem, Inc. on 09/25/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 12/03/2018
Obinutuzumab + Lenalidomide Submitted by Genentech, Inc. on 12/06/2018
Lenalidomide + Rituximab Submitted by Celgene Corporation on 03/22/2019
Lenalidomide + Rituximab Submitted by Celgene Corporation on 05/28/2019
Polatuzumab vedotin Submitted by Genentech, Inc. on 06/10/2019
Siltuximab Submitted by EUSA Pharma, Inc. on 08/01/2019
Obinutuzumab + Lenalidomide Submitted by Genentech, Inc. on 08/01/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 08/09/2019
Zanubrutinib Submitted by BeiGene, Ltd. on 11/14/2019
Polatuzumab Vedotin Submitted by Genentech, Inc. on 12/17/2019
Ibrutinib Submitted by Pharmacyclics, LLC on 12/19/2019
2 Gy x 2 fractions Submitted by Oncology Analytics, Inc. on 02/08/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 04/17/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Tazemetostat Submitted by Epizyme Inc. on 06/18/2020
Selinexor Submitted by Karyopharm Therapeutics on 06/23/2020
Brexucabtagene Autoleucel Submitted by Kite on 07/24/2020
Tafasitamab-cxix in combo with Lenalidomide Submitted by MorphoSys AG and Incyte Corporation on 08/03/2020
NGS clarification Submitted by Adaptive Biotechnologies on 09/01/2020
Siltuximab Submitted by Castleman Disease Collaborative Network (CDCN) on 09/08/2020
Axicabtagene ciloleucel Submitted by Kite on 09/18/2020
Axicabtagene ciloleucel Submitted by Kite on 12/08/2020
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 02/08/2021
Umbralisib Submitted by TG Therapeutics, Inc. on 02/09/2021
Umbralisib Submitted by TG Therapeutics, Inc. on 02/10/2021
Umbralisib Submitted by TG Therapeutics, Inc. on 03/12/2021
Loncastuximab tesirine‐lpyl Submitted by ADC Therapeutics on 04/23/2021
Umbralisib Submitted by TG Therapeutics, Inc. on 05/19/2021
Measurable Residual Disease (MRD) Testing in Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma Submitted by Adaptive Biotechnologies on 08/23/2021
Tafasitamab-cxix Submitted by Dr. Wei Jiang, PhD and Dr. Michael Cuozzo, PharmD on 09/01/2021
Zanubrutinib Submitted by BeiGene, Ltd. on 09/15/2021
Zanubrutinib Submitted by BeiGene, Ltd. on 09/17/2021
Axicabtagene Ciloleucel Submitted by Kite on 12/12/2021
Axicabtagene Ciloleucel Submitted by Kite on 12/12/2021
polatuzumab vedotin-piiq Submitted by Genentech, Inc. on 12/15/2021
Duvelisib Submitted by Secura Bio, Inc. on 01/10/2022
obinuzutuzumab Submitted by Genentech, Inc. on 02/14/2022
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 04/05/2022
glucarpidase Submitted by BTG International on 05/20/2022
Tisagenlecleucel Submitted by Novartis Pharmaceuticals Corporation on 06/01/2022
zanubrutinib Submitted by BeiGene, Ltd. on 06/06/2022
zanubrutinib Submitted by BeiGene, Ltd. on 06/06/2022
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 06/13/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 06/21/2022
Lisocabtagene maraleucel Submitted by on 06/24/2022
ibrutinib Submitted by Pharmacyclics, LLC on 06/30/2022
lisocabtagene maraleucel; liso-cel Submitted by Bristol-Myers Squibb Company on 08/04/2022
acalabrutinib Submitted by AstraZeneca on 08/15/2022
acalabrutinib + acid-reducing agents Submitted by AstraZeneca on 09/01/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 12/19/2022
Lisocabtagene maraleucel Submitted by Bristol-Myers Squibb Company on 01/05/2023
Pirtobrutinib Submitted by Eli Lilly and Company on 01/27/2023

Bladder/Penile Cancers Panel

Atezolizumab Submitted by Genentech, Inc. on 06/20/2018
Cystoscopy Submitted by Photocure, Inc. on 08/07/2018
Molecular testing Submitted by Foundation Medicine, Inc. on 08/23/2018
Cxbladder Monitor Assay Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/31/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 10/23/2018
Erdafitinib Submitted by Janssen Scientific Affairs, LLC on 04/15/2019
Atezolizumab Submitted by Genentech, Inc. on 06/18/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/09/2019
Erdafitinib Submitted by Janssen Scientific Affairs, LLC on 07/30/2019
Genetic Alterations Submitted by Foundation Medicine, Inc. on 08/26/2019
Atezolizumab Submitted by Genentech, Inc. on 08/27/2019
Enfortumab vedotin Submitted by Seattle Genetics, Inc. on 12/06/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 01/08/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/30/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Avelumab Submitted by EMD Serono and Pfizer Inc. on 06/30/2020
Patient Advocate Recommendations Submitted by Bladder Cancer Advocacy Network (BCAN) on 07/27/2020
Urothelial tumor markers Submitted by Pacific Edge Diagnostics USA, Ltd. on 08/13/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 08/28/2020
Avelumab Submitted by EMD Serono and Pfizer Inc. on 09/18/2020
Enfortumab vedotin Submitted by Seagen Inc on 02/16/2021
Atezolizumab Submitted by Genentech, Inc. on 03/08/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/15/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/03/2021
Enfortumab vedotin-ejfv Submitted by Seagen Inc on 07/13/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 08/20/2021
CGP Submitted by Guardant Health on 06/22/2022
TMB Submitted by Cleveland Clinic on 07/25/2022
TMB Submitted by Foundation Medicine, Inc. on 07/25/2022
Nadofaragene firadenovec Submitted by Ferring Pharmaceuticals on 12/16/2022

Bone Cancer Panel

Cabozantinib Submitted by Exelixis Inc. on 04/12/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Glucarpidase Submitted by BTG International on 12/18/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/30/2020
Cabozantinib Submitted by Exelixis Inc. on 04/15/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 04/15/2021
Comprehensive genomic profiling (CGP) Submitted by Illumina Inc. on 04/27/2021
Include nivolumab in combination with ipilimumab. Submitted by Bristol-Myers Squibb Company on 04/11/2022
Submission to include lurbinectedin for Ewing sarcoma Submitted by Jazz Pharmaceuticals Inc. on 07/29/2022

Breast Cancer Panel

Paxman Scalp Cooling System Submitted by Paxman Coolers Limited on 06/12/2018
Ribociclib + Fulvestrant Submitted by AstraZeneca on 06/28/2018
Ribociclib + Fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 06/29/2018
Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Oncotype DX Breast Recurrence Score® (RS) assay Submitted by Genomic Health, Inc. on 07/03/2018
Next-generation sequencing (NGS) Submitted by Foundation Medicine, Inc. on 07/03/2018
Radiofrequency spectroscopy Submitted by Dune Medical, Inc. on 07/05/2018
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2018
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2018
Talazoparib Submitted by Pfizer Inc. on 10/16/2018
Atezolizumab Submitted by Genentech, Inc. on 10/20/2018
Ado-trastuzumab emtansine Submitted by Genentech, Inc. on 12/05/2018
Neratinib Submitted by Puma Biotechnology on 12/21/2018
Genetic Testing Guidelines Submitted by Targeted Medical Education (TME) on 02/18/2019
Trastuzumab and Hyaluronidase-oysk Submitted by Genentech, Inc. on 02/28/2019
Atezolizumab Submitted by Genentech, Inc. on 03/08/2019
Alpelisib Submitted by Novartis Pharmaceuticals Corporation on 05/24/2019
Larotrectinib Submitted by Bayer HealthCare on 05/28/2019
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 06/06/2019
Neratinib Submitted by Puma Biotechnology on 06/10/2019
Neratinib + Capecitabine Submitted by Puma Biotechnology on 06/10/2019
Locoregional therapies Submitted by Society of Interventional Oncology on 06/14/2019
Trastuzumab-dkst Submitted by Mylan N.V. on 06/26/2019
Oncotype DX® Breast DCIS Score™ assay Submitted by Genomic Health, Inc. on 07/15/2019
Trastuzumab-anns Submitted by Amgen Inc. on 07/19/2019
Subclinical Lymphedema Submitted by Vanderbilt University School of Nursing on 07/19/2019
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
Genomic Assays Submitted by Myriad Genetic Laboratories, Inc. on 07/23/2019
Trastuzumab-dttb Submitted by Samsung Bioepis Co., Ltd on 07/24/2019
Atezolizumab, Pertuzumab, Ado-trastuzumab Emtansine Submitted by Genentech, Inc. on 07/24/2019
Next-Generation Sequencing Assays Submitted by Foundation Medicine, Inc. on 07/24/2019
Breast Cancer Index (BCI) Submitted by Biotheranostics on 07/25/2019
Denosumab Submitted by My Style Matters on 07/25/2019
Ixabepilone + Capecitabine Submitted by R-Pharm US on 07/30/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 09/29/2019
Abemaciclib Submitted by Eli Lilly and Company on 10/29/2019
Tucatinib Submitted by Seattle Genetics, Inc. on 12/24/2019
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. and AstraZeneca on 01/02/2020
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 01/27/2020
Estrogen receptor alpha-36 testing Submitted by Christina Rosati on 02/25/2020
Neratinib + capecitabine Submitted by Puma Biotechnology on 02/27/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/18/2020
docetaxel_carboplatin_trastuzumab Submitted by Guangdong Academy of Medical Sciences on 03/22/2020
Tucatinib Submitted by Seattle Genetics, Inc. on 04/17/2020
Sacituzumab govitecan-hziy Submitted by Immunomedics, Inc. on 04/22/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Alpelisib + fulvestrant Submitted by Novartis Pharmaceuticals Corporation on 05/12/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 05/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
TMB testing Submitted by Foundation Medicine, Inc. on 06/22/2020
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Submitted by Genentech, Inc. on 06/29/2020
Ado-trastuzumab emtansine Submitted by Linda W. Wilson, MD on 07/08/2020
Radiation Therapy Submitted by American Society for Radiation Oncology on 07/20/2020
21-Gene RT-PCR assay Submitted by Exact Sciences Inc. on 07/28/2020
FES PET Submitted by Zionexa on 07/29/2020
PET/CT Submitted by Society of Interventional Oncology on 07/30/2020
EndoPredict Submitted by Myriad Genetic Laboratories, Inc. on 08/01/2020
PET/CT Submitted by MD Anderson Cancer Center on 08/04/2020
Pertuzumab + ado-trastuzumab emtansine Submitted by Genentech, Inc. on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics on 08/05/2020
Breast Cancer Index Submitted by Biotheranostics on 08/05/2020
L-Dex Submitted by ImpediMed, Inc. on 08/05/2020
Neratinib Submitted by Puma Biotechnology on 08/05/2020
NGS assay Submitted by Guardant Health on 08/06/2020
NGS assay Submitted by Foundation Medicine, Inc. on 08/06/2020
TMB testing Submitted by Foundation Medicine, Inc. on 09/15/2020
Neratinib Submitted by Puma Biotechnology on 10/05/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 11/16/2020
Atezolizumab + albumin-bound paclitaxel Submitted by Genentech, Inc. on 12/02/2020
Capecitabine Submitted by Sun Yat-sen University Cancer Center on 01/29/2021
Atezolizumab Submitted by Genentech, Inc. on 03/16/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/08/2021
Olaparib Submitted by AstraZeneca on 04/12/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 04/26/2021
Capecitabine Submitted by Sun Yat-sen University Cancer Center on 05/21/2021
Comprehensive Genomic Profiling Submitted by Illumina Inc. on 05/26/2021
Olaparib Submitted by AstraZeneca on 06/09/2021
Cabazitaxel Submitted by Sanofi on 06/11/2021
Durvalumab Submitted by AstraZeneca on 07/01/2021
Neratinib Submitted by Puma Biotechnology on 07/07/2021
Larotrectinib Submitted by Bayer HealthCare on 07/08/2021
Guardant360 CDx Submitted by Guardant Health on 07/12/2021
APBI Dosing Submitted by Schwartzberg Center for Minimally Invasive Breast Surgery on 07/13/2021
Vaginal pH modulator Submitted by Evofem Biosciences, Inc. on 07/13/2021
Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 07/15/2021
Tucatinib Submitted by Seagen Inc on 07/15/2021
Neratinib Submitted by Puma Biotechnology on 07/18/2021
Olaparib Submitted by AstraZeneca on 07/20/2021
12-Gene (EndoPredict) Assay Submitted by Myriad Genetic Laboratories, Inc. on 07/20/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 07/27/2021
ctDNA Submitted by Natera, Inc. on 07/28/2021
ctDNA Submitted by Natera, Inc. on 07/28/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Atezolizumab Submitted by Genentech, Inc. on 08/27/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/02/2021
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/07/2021
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 09/21/2021
Ado-trastuzumab emtansine Submitted by Genentech, Inc. on 09/29/2021
Ribociclib Submitted by Novartis Pharmaceuticals Corporation on 10/11/2021
Abemaciclib Submitted by Eli Lilly and Company on 10/14/2021
Abemaciclib Submitted by Agilent Technologies, Inc. on 10/20/2021
Abemaciclib Submitted by Eli Lilly and Company on 10/28/2021
Docetaxel plus carboplatin Submitted by Guangdong Academy of Medical Sciences on 11/14/2021
bioimpedance spectroscopy Submitted by Cleveland Clinic on 11/20/2021
Adjuvant Olaparib Submitted by AstraZeneca on 12/13/2021
tucatinib_trastuzumab_capecitabine Submitted by The University of Texas MD Anderson Cancer Center on 01/25/2022
tucatinib Submitted by Seagen Inc on 02/03/2022
bioimpedance spectroscopy Submitted by Vanderbilt University School of Nursing on 02/09/2022
olaparib Submitted by AstraZeneca on 03/24/2022
ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. and AstraZeneca on 06/06/2022
ribociclib Submitted by Novartis Pharmaceuticals Corporation on 06/06/2022
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 06/10/2022
eribulin Submitted by Eisai Inc. on 06/11/2022
70-gene assay Submitted by Agendia, Inc. on 06/20/2022
neratinib_fulvestrant_trastuzumab Submitted by Puma Biotechnology on 07/18/2022
SBRT Submitted by Genesis Care/Michigan Healthcare Professionals on 07/22/2022
IMRT Submitted by Genesis Care/Michigan Healthcare Professionals on 07/22/2022
zoladex Submitted by TerSera Therapeutics on 07/22/2022
CGP Submitted by Guardant Health on 07/25/2022
NGS Submitted by Foundation Medicine, Inc. on 07/27/2022
Perjeta and Herceptin Submitted by Genentech, Inc. on 07/29/2022
fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 08/08/2022
Sacituzumab govitecan-hziy Submitted by Gilead Sciences, Inc. on 09/12/2022
Elacestrant Submitted by Stemline Therapeutics, Inc. on 01/30/2023

Breast Cancer Risk Reduction Panel

riskScore™ Submitted by Myriad Genetic Laboratories, Inc. on 07/06/2020
BBDRisk Dx® MAAA (Multianalyte Assays with Algorithmic Analysis) Submitted by Silbiotech on 07/10/2020
Suggested Updates to CanRisk Tool (BOADICEA) Submitted by Centre for Cancer Genetic Epidemiology on 06/16/2022

Breast Cancer Screening and Diagnosis Panel

Digital Breast Tomosynthesis Submitted by Hologic, Inc. on 10/28/2018

Cancer in People with HIV/Kaposi Sarcoma Panel

Pomalidomide Submitted by Bristol-Myers Squibb Company on 05/19/2020
Galleri Submitted by Grail, Inc. on 08/02/2021

Cancer-Associated Venous Thromboembolic Disease Panel

Apixaban Submitted by Bristol-Myers Squibb Company on 12/21/2018
Apixaban Submitted by Bristol-Myers Squibb Company on 11/06/2019
Apixaban Submitted by Bristol-Myers Squibb Company on 04/06/2020
Andexanet alfa Submitted by Bristol-Myers Squibb Company on 06/25/2020
Acute DVT Submitted by Society of Interventional Oncology on 10/27/2020

Central Nervous System Cancers Panel

Osimertinib Submitted by AstraZeneca on 04/19/2018
Bevacizumab Submitted by Munson Medical Oncology on 05/02/2018
Glucarpidase Submitted by BTG International on 09/13/2018
Regorafenib Submitted by Bayer HealthCare on 12/10/2018
Osimertinib Submitted by AstraZeneca on 01/17/2019
Neratinib + Capecitabine Submitted by Puma Biotechnology on 04/05/2019
Vitrakvi Submitted by Bayer HealthCare on 05/28/2019
Neratinib + Capecitabine Submitted by Puma Biotechnology on 06/10/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/18/2019
Bevacizumab-awwb Submitted by Amgen Inc. on 07/19/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Osimertinib Submitted by AstraZeneca on 04/14/2020
Tucatinib Submitted by Seattle Genetics, Inc. on 04/17/2020
Selumetinib Submitted by AstraZeneca on 05/04/2020
Selumetinib Submitted by AstraZeneca on 05/04/2020
Tucatinib Submitted by Seattle Genetics, Inc. on 05/29/2020
Aminolevulinic acid hydrochloride Submitted by NX Development Corp on 06/02/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/23/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/24/2020
Laser Interstitial Thermal Therapy (LITT) Submitted by Washington University School of Medicine; Department of Neurological Surgery on 08/28/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/18/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 12/11/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Selpercatinib Submitted by Eli Lilly and Company on 06/16/2021
Belzutifan Submitted by Merck & Co., Inc. on 08/19/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/09/2021
Tepotinib Submitted by EMD Serono on 09/13/2021
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 09/22/2021

Cervical/Uterine Cancers Panel

Trastuzumab Submitted by Genentech, Inc. on 04/26/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 06/12/2018
Radiation Therapy Submitted by American Society for Radiation Oncology on 04/30/2019
PCR-based Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 05/17/2019
Lenvatinib in combination with pembrolizumab Submitted by Eisai Inc. on 06/28/2019
Bevacizumab-awwwb Submitted by Amgen Inc. on 07/19/2019
Entrectinib and appropriate NTRK gene fusion testing Submitted by Genentech, Inc. on 08/15/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/17/2019
Nivolumab for Vulvar Cancer Submitted by Bristol-Myers Squibb Company on 10/17/2019
Nivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb Company on 12/04/2019
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab dosing for Vulvar Cancer Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020
Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GlaxoSmithKline on 05/15/2020
Pembrolizumab for Cervical Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for Vulvar Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab and TMB testing for Cervical Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Pembrolizumab and TMB testing for Vulvar Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Pembrolizumab and TMB testing for Uterine Neoplasms Submitted by Foundation Medicine, Inc. on 06/30/2020
Avelumab Submitted by EMD Serono on 08/11/2020
Oral selixinor for Endometrial Carcinoma Submitted by Karyopharm Therapeutics on 01/21/2021
Lenvatinib in combination with Pembrolizumab Submitted by Eisai Inc. on 02/11/2021
Lenvatinib and pembrolilzumab for Uterine Neoplasms Submitted by Eisai Inc. on 02/11/2021
Pembrolizumab in combination with Lenvatinib Submitted by Merck & Co., Inc. on 03/19/2021
Pembrolizumab and Lenvatinib for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 04/21/2021
Dostarlimab-gxly (Uterine Neoplasms) Submitted by GlaxoSmithKline on 04/22/2021
Dostarlimab-gxly for Uterine Neoplasms Submitted by GlaxoSmithKline on 04/28/2021
Cabozantinib Submitted by Exelixis Inc. on 05/05/2021
Cabozantinib for Uterine Neoplasms Submitted by Exelixis Inc. on 05/05/2021
TMB Testing for Cervical Cancer Submitted by Illumina Inc. on 05/13/2021
Comprehensive genomic profiling for Uterine Neoplasms Submitted by Illumina Inc. on 05/13/2021
Comprehensive genomic profiling for Vulvar Cancer Submitted by Foundation Medicine, Inc. on 05/14/2021
Tisotumab vedotin-tftv for Cervical Cancer Submitted by Seagen Inc on 05/14/2021
Comprehensive genomic profiling for Uterine Neoplasms Submitted by Foundation Medicine, Inc. on 05/14/2021
Genetic Risk Assessment for Uterine Neoplasms Submitted by Illumina Inc., Ambry Genetics, Quest Diagnostics, GeneDx and Myriad Genetic Laboratories, Inc. on 05/21/2021
Lenvatinib in combination with Pembrolizumab Submitted by Eisai Inc. on 06/17/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/18/2021
Pembrolizumab in combination with Lenvatinib Submitted by Merck & Co., Inc. on 07/22/2021
Pembrolizumab (Uterine) Submitted by Merck & Co., Inc. on 09/20/2021
Fam-trastuzumab deruxtecan-nxki (Uterine) Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 09/24/2021
Pembrolizumab in combination with chemotherapy, with or without bevacizumab for Cervical Cancer Submitted by Merck & Co., Inc. on 10/14/2021
Dostarlimab-gxly (Uterine) Submitted by GlaxoSmithKline on 10/18/2021
Lenvatinib in combination with pembrolizumab (Uterine) Submitted by Eisai Inc. on 11/03/2021
Cemiplimab Submitted by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. on 02/10/2022
Adjuvant Therapy in Uterine Cancer Stage I and II Submitted by Assam Cancer Care Foundation on 03/16/2022
Pembrolizumab (Uterine) Submitted by Merck & Co., Inc. on 03/23/2022
Pembrolizumab in combination with lenvatinib (Uterine) Submitted by Merck & Co., Inc. on 03/24/2022
Nivolumab with Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab with Ipilimumab (Uterine) Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO Guideline reference Submitted by American Society for Radiation Oncology on 04/26/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 05/11/2022
Comprehensive Genomic Profiling (Uterine) Submitted by Foundation Medicine, Inc. on 05/19/2022
Tisotumab vedotin in combination with pembrolizumab Submitted by Seagen Inc on 05/27/2022
Dostarlimab-glxy (Uterine) Submitted by GlaxoSmithKline on 06/08/2022
Selpercatinib for RET fusion-positive tumors Submitted by Eli Lilly and Company on 09/21/2022

Chronic Myeloid Leukemia Panel

Nilotinib Submitted by Novartis Pharmaceuticals Corporation on 05/02/2019
Ponatinib Submitted by Takeda Oncology on 10/21/2020
Asciminib Submitted by Novartis Pharmaceuticals Corporation on 10/20/2021
Asciminib Submitted by Novartis Pharmaceuticals Corporation on 10/29/2021
Ponatinib Submitted by Takeda Oncology on 11/15/2021
Ponatinib Submitted by Takeda Oncology on 04/08/2022

CLL/SLL/Hairy Cell Leukemia Panel

TP53 genetic sequencing Submitted by Illumina Inc. on 04/06/2018
Ibrutinib Submitted by Pharmacyclics, LLC on 06/20/2018
Venetoclax Submitted by AbbVie, Inc. on 06/21/2018
Moxetumomab pasudotox-tdfk Submitted by AstraZeneca on 09/15/2018
Duvelisib Submitted by Verastem, Inc. on 09/25/2018
Ibrutinib Submitted by Pharmacyclics, LLC on 12/20/2018
Acalabrutinib Submitted by AstraZeneca on 12/21/2018
clonoSEQ assay Submitted by Adaptive Biotechnologies on 05/13/2019
Venetoclax Submitted by AbbVie, Inc. on 05/16/2019
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. on 06/05/2019
Venetoclax + Rituximab Submitted by AbbVie, Inc. on 06/05/2019
Acalabrutinib Submitted by AstraZeneca on 06/26/2019
Ibrutinib Submitted by Pharmacyclics, LLC on 06/28/2019
Acalabrutinib Submitted by AstraZeneca on 07/09/2019
Rituximab-abbs Submitted by Teva Pharmaceuticals, Inc. on 09/23/2019
Acalabrutinib Submitted by AstraZeneca on 11/21/2019
Zanubrutinib Submitted by BeiGene, Ltd. on 12/17/2019
Moxetumomab pasudotox-tdfk Submitted by Innate Pharma, Inc. on 05/08/2020
clonoSEQ Submitted by Adaptive Biotechnologies on 05/12/2020
Ibrutinib Submitted by Pharmacyclics, LLC on 05/15/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 05/15/2020
Acalabrutinib Submitted by AstraZeneca on 05/23/2020
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. on 06/02/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 08/03/2020
Venetoclax + Obinutuzumab Submitted by AbbVie, Inc. on 09/11/2020
clonoSEQ Submitted by Adaptive Biotechnologies on 09/30/2020
Rasburicase Submitted by Sanofi on 10/12/2020
Ibrutinib Submitted by Pharmacyclics, LLC and Janssen Biotech, Inc. on 12/06/2020
Venetoclax Submitted by Genentech, Inc. and AbbVie, Inc. on 01/11/2021
MRD Submitted by Adaptive Biotechnologies on 05/14/2021
Vemurafenib + rituximab Submitted by Genentech, Inc. on 05/21/2021
Zanubrutinib Submitted by BeiGene, Ltd. on 12/23/2021
Zanubrutinib Submitted by BeiGene, Ltd. on 12/23/2021
Ibrutinib Submitted by AbbVie, Inc., Janssen Biotech, Inc. and Pharmacyclics, LLC on 05/19/2022
Acalabrutinib Submitted by AstraZeneca on 05/27/2022
MRD testing Submitted by Adaptive Biotechnologies on 05/27/2022
Acalabrutinib Submitted by AstraZeneca on 06/09/2022
Zanubrutinib Submitted by BeiGene, Ltd. on 07/26/2022
Venetoclax + Obinutuzumab Submitted by Genentech, Inc. and AbbVie, Inc. on 08/30/2022
Acalabrutinib Submitted by AstraZeneca on 12/05/2022
Zanubrutinib Submitted by on 12/13/2022
Zanubrutinib Submitted by BeiGene, Ltd. on 01/19/2023

Colon/Rectal/Anal Cancers Panel

Trastuzumab + Pertuzumab Submitted by Genentech, Inc. on 05/11/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/11/2018
Immunoscore testing Submitted by HalioDx on 07/24/2018
Radiation Therapy Submitted by American Society for Radiation Oncology on 07/31/2018
Yttrium 90 Submitted by Sirtex Medical Inc. on 08/02/2018
Atezolizumab Submitted by Genentech, Inc. on 08/07/2018
Fluoropyrimidines Submitted by Kenneth E. Surprenant on 08/08/2018
Comprehensive Genomic Profiling (CGP) assay Submitted by Foundation Medicine, Inc. on 08/09/2018
Yttrium 90 Submitted by Sirtex Medical Inc. on 08/10/2018
Vitrakvi Submitted by Bayer HealthCare on 12/10/2018
Encorafenib + Binimetinib + Cetuximab Submitted by Array BioPharma Inc. on 02/26/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/19/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 05/03/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/03/2019
Transanal full thickness local excision Submitted by Ascension St. John Hospital on 06/04/2019
Encorafenib + Binimetinib + Cetuximab Submitted by Array BioPharma Inc. on 07/16/2019
Bevacizumab-awwb Submitted by Amgen Inc. on 07/19/2019
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 07/24/2019
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 07/24/2019
Levoleucovorin Submitted by Acrotech Biopharma LLC on 07/25/2019
DPYD genetic testing Submitted by University of Michigan College of Pharmacy on 07/29/2019
MSI Assays Submitted by Promega Corporation on 07/29/2019
Regorafenib + Nivolumab Submitted by Bayer HealthCare on 07/30/2019
yttrium-90 Submitted by Society of Interventional Oncology on 08/08/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Comprehensive genomic profiling (CGP) Submitted by Guardant Health on 01/30/2020
Pembrolizumab for Anal Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/01/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/01/2020
Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 06/10/2020
Pembrolizumab for Small Bowel Adenocarcinoma Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Immunoscore assay Submitted by HalioDx on 06/25/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 06/30/2020
Fam-trastuzumab deruxtecan-nxki Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 07/09/2020
Post-surgical tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Colon Cancer Submitted by Natera, Inc. on 07/13/2020
Post-surgical tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
Tumor-informed ctDNA for Rectal Cancer Submitted by Natera, Inc. on 07/13/2020
yttrium-90 Submitted by Society of Interventional Oncology on 07/14/2020
Next-generation sequencing (NGS) Submitted by Guardant Health on 07/20/2020
Circulating Tumor DNA (ctDNA) Submitted by Colorectal Cancer Alliance on 08/10/2020
Pralsetinib Submitted by Blueprint Medicines on 09/08/2020
Tumor Mutational Burden (TMB) for Small Bowel Adenocarcinoma Submitted by Foundation Medicine, Inc. on 09/16/2020
Tumor Mutational Burden (TMB) for Colon Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Tumor Mutational Burden (TMB) for Rectal Cancer Submitted by Foundation Medicine, Inc. on 09/18/2020
Lenvatinib + Pembrolizumab Submitted by Eisai Inc. on 10/04/2020
Pembrolizumab for Colon Cancer Submitted by Merck & Co., Inc. on 12/04/2020
Pembrolizumab for Rectal Cancer Submitted by Merck & Co., Inc. on 12/04/2020
Trifluridine and Tipiracil Submitted by Taiho Oncology, Inc. on 02/16/2021
Panitumumab Submitted by Amgen Inc. on 06/24/2021
CGP for Colon Cancer Submitted by Foundation Medicine, Inc. on 06/29/2021
CGP for Rectal Cancer Submitted by Foundation Medicine, Inc. on 06/29/2021
ctDNA for Colon Cancer Submitted by Clinical Genomics Pathology, Inc on 06/30/2021
ctDNA for Rectal Cancer Submitted by Clinical Genomics Pathology, Inc on 06/30/2021
Encorafenib + Cetuximab Submitted by Pfizer Inc. on 07/01/2021
CGP for Colon Cancer Submitted by Guardant Health on 07/02/2021
CGP for Rectal Cancer Submitted by Guardant Health on 07/02/2021
Dostarlimab-gxly for Colon Cancer Submitted by GlaxoSmithKline on 08/17/2021
Dostarlimab-gxly for Rectal Cancer Submitted by GlaxoSmithKline on 08/17/2021
Dostarlimab-gxly for Small Bowel Adenocarcinoma Submitted by GlaxoSmithKline on 08/17/2021
Nivolumab + ipilimumab for Anal Carcinoma Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + ipilimumab for Small Bowel Adenocarcinoma Submitted by Bristol-Myers Squibb Company on 04/11/2022
Surveillance for Anal Carcinoma Submitted by Patient on 05/09/2022
DPYD variant testing for Anal Carcinoma Submitted by Invitae on 08/01/2022
Selpercatinib for Colon/Rectal Cancer Submitted by Eli Lilly and Company on 09/21/2022
Selpercatinib for Small Bowel Adenocarcinoma Submitted by Eli Lilly and Company on 09/21/2022
Tucatinib + trastuzumab for Rectal Cancer Submitted by Seagen Inc on 01/20/2023
Tucatinib + trastuzumab for Colon Cancer Submitted by Seagen Inc on 01/20/2023

Colorectal Cancer Screening Panel

Average-risk CRC screening Submitted by Exact Sciences Inc. on 10/29/2018
Epi proColon Submitted by Epigenomics Inc. on 12/05/2019
Epi proColon Submitted by Epigenomics Inc. on 09/28/2020
FIT-DNA-based testing Submitted by Exact Sciences Inc. on 10/13/2020
mt-s DNA Submitted by Exact Sciences Inc. on 03/08/2021
mt-s DNA Test Submitted by on 10/06/2021

Esophageal/Gastric Cancers Panel

Trifluridine/Tipiracil Submitted by Taiho Oncology, Inc. on 07/13/2018
Trastuzumab Submitted by Eli Lilly and Company on 07/17/2018
Principles of Pathologic Review Submitted by Foundation Medicine, Inc. on 09/11/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 01/29/2019
Trastuzumab-dkst Submitted by Mylan N.V. on 06/26/2019
Trastuzumab-anns Submitted by Amgen Inc. on 07/19/2019
Scalp cooling system for Esophageal and Gastric Submitted by Paxman Coolers Limited on 07/26/2019
Regorafenib plus nivolumab for Gastric Cancer Submitted by Bayer HealthCare on 07/30/2019
Trastuzumab-dttb Submitted by Samsung Bioepis Co., Ltd on 08/02/2019
Entrectinib and appropriate NTRK gene fusion testing Submitted by Genentech, Inc. on 08/15/2019
Comprehensive genetic profiling Submitted by Foundation Medicine, Inc. on 09/05/2019
Wide area transepithelial sampling for Esophageal Cancer Submitted by CDx Diagnostics on 09/06/2019
Pembrolizumab Submitted by Oncology Analytics, Inc. on 09/18/2019
PCR-based microsatellite instability assays for Esophageal and Gastric Cancer Submitted by Promega Corporation on 09/23/2019
Nivolumab for Esophageal Cancer Submitted by Bristol-Myers Squibb Company on 09/30/2019
Plasma-based comprehensive genomic profiling for Esophageal Cancer Submitted by Guardant Health on 01/30/2020
Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc. on 03/12/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Esophageal and Esophagogastric Cancer Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab for Gastric Cancer Submitted by Merck & Co., Inc. on 04/29/2020
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. on 06/04/2020
Fam-trastuzumab deruxtecan-nxki (Esophageal and Gastric Cancers) Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 06/04/2020
Nivolumab for Esophageal squamous cell carcinoma Submitted by Bristol-Myers Squibb Company on 06/11/2020
Pembrolizumab for TMB-H for Esophageal Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Pembrolizumab for TMB for Gastric Cancer Submitted by Merck & Co., Inc. on 06/17/2020
Tumor mutational burden (TMB) testing for Esophageal Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Tumor mutational burden (TMB) testing for Gastric Cancer Submitted by Foundation Medicine, Inc. on 06/22/2020
Comprehensive genomic profiling for Esophageal Cancer Submitted by Foundation Medicine, Inc. on 08/26/2020
Tumor mutational burden (TMB) testing for Gastric Cancer Submitted by Foundation Medicine, Inc. on 08/26/2020
Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/26/2020
Pembrolizumab with chemotherapy for Esophageal Cancer Submitted by Merck & Co., Inc. on 09/21/2020
Nivolumab for Esophageal Cancer Submitted by Bristol-Myers Squibb Company on 09/23/2020
Nivolumab for Gastric Cancer Submitted by Bristol-Myers Squibb Company on 09/23/2020
Pembrolizumab for Esophageal Cancer Submitted by Merck & Co., Inc. on 11/04/2020
Fam-trastuzumab deruxtecan-nxki (Esophageal and Gastric Cancers) Submitted by Daiichi-Sankyo, Inc. and AstraZeneca on 01/21/2021
Pembrolizumab in combination with oxaliplatin and fluoropyrimidine based chemotherapy (Esophageal) Submitted by Merck & Co., Inc. on 03/23/2021
Pembrolizumab in combination with oxaliplatin and fluoropyrimidine based chemotherapy (Esophageal) Submitted by Merck & Co., Inc. on 03/31/2021
Nivolumab in combination with oxaliplatin and fluorouracil or capecitabine (Esophageal) Submitted by Bristol-Myers Squibb Company on 04/16/2021
Nivolumab in combination with oxaliplatin and fluorouracil or capecitabine (Gastric) Submitted by Bristol-Myers Squibb Company on 04/16/2021
Pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 05/06/2021
Pembrolizumab (Gastric) Submitted by Merck & Co., Inc. on 05/18/2021
Pembrolizumab, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy (Gastric) Submitted by Merck & Co., Inc. on 06/04/2021
Nivolumab in combination with chemotherapy (Esophageal) Submitted by Bristol-Myers Squibb Company on 06/07/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/07/2021
Pembrolizumab (Gastric) Submitted by Merck & Co., Inc. on 06/18/2021
Trifluridine and tipiracil (Esophageal and Gastric) Submitted by Taiho Oncology, Inc. on 07/26/2021
Radiation dosing and techniques (Esophageal) Submitted by American Society for Radiation Oncology on 07/27/2021
Plasma-based comprehensive genomic profiling Submitted by Guardant Health on 08/08/2021
Comprehensive genomic profiling (Esophageal) Submitted by Foundation Medicine, Inc. on 08/10/2021
Comprehensive genomic profiling (Gastric) Submitted by Foundation Medicine, Inc. on 08/10/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Genetic Risk Assessment (Gastric) Submitted by Ambry Genetics, GeneDx Inc, Myriad Genetic Laboratories Inc, Quest Diagnostics Laboratories and AliveAndKickn on 08/17/2021
Methylation-based blood test (Esophageal and Gastric) Submitted by Grail, Inc. on 08/22/2021
Pembrolizumab in combination with chemotherapy Submitted by Merck & Co., Inc. on 08/30/2021
Nivolumab in combination with chemotherapy Submitted by Bristol-Myers Squibb Company on 09/24/2021
Nivolumab in combination with chemotherapy Submitted by Bristol-Myers Squibb Company on 01/26/2022
Nivolumab in combination with ipilimumab for tTMB-H tumors Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab with Ipilimumab for (tTMB-H) (Gastric) Submitted by Bristol-Myers Squibb Company on 04/11/2022
Tislelizumab (Esophageal) Submitted by Novartis Pharmaceuticals Corporation on 05/26/2022
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/31/2022
Spatialomics risk stratification (Esophageal) Submitted by Castle Biosciences on 07/26/2022
Nivolumab + Chemotherapy and Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 08/01/2022
Genetic risk assessment (Gastric) Submitted by Myriad Genetic Laboratories, Inc., Illumina Inc., Ambry Genetics, AliveAndKickn, FORCE, Quest Diagnostics and GeneDx on 08/01/2022
Selpercatinib (Esophageal) Submitted by Eli Lilly and Company on 09/21/2022
Selpercatinib (Gastric) Submitted by Eli Lilly and Company on 09/21/2022

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Panel

RAD51D gene variations Submitted by Hines & Associates, Inc. on 02/28/2019
Genetic Testing Submitted by Myriad Genetic Laboratories, Inc. on 04/01/2019
Prostate Cancer Testing Criteria Submitted by Myriad Genetic Laboratories, Inc. on 04/02/2019
PALB2 testing criteria Submitted by Myriad Genetic Laboratories, Inc. on 04/03/2019
Personal history of ovarian carcinoma Submitted by Myriad Genetic Laboratories, Inc. on 04/03/2019
Genetic Testing Submitted by Oneinforty on 04/24/2019
Genetic Testing Submitted by University of Minnesota Medical Center on 05/31/2019
BARD1- and RAD51D-associated breast cancer risk Submitted by Ambry Genetics on 10/03/2019
Multi-gene testing Submitted by Ambry Genetics on 10/03/2019
Olaparib Submitted by AstraZeneca on 10/07/2019
Breast Cancer diagnosis less than 66 years old Submitted by Myriad Genetic Laboratories, Inc. on 03/25/2020
High Penetrance Genes Submitted by Myriad Genetic Laboratories, Inc. on 03/25/2020
Prostate Cancer Testing Criteria Submitted by Myriad Genetic Laboratories, Inc. on 04/01/2020
Polygenic Risk Scores Submitted by Myriad Genetic Laboratories, Inc. on 03/16/2021
Polygenic Risk Scores Submitted by Bright Pink on 03/17/2021
Genetic Testing Criteria Submitted by Ambry Genetics, Illumina Inc., GeneDx, Quest Diagnostics and Myriad Genetic Laboratories, Inc. on 03/17/2021
Genetic testing Submitted by Myriad Genetic Laboratories, Inc., Illumina Inc., Ambry Genetics, GenPath Oncology, AliveAndKickn and Quest Diagnostics on 02/22/2022
Polygenic risk scores Submitted by Myriad Genetic Laboratories, Inc. on 03/28/2022
Genetic testing Submitted by Invitae on 03/31/2022

Genetic/Familial High-Risk Assessment: Colorectal Panel

Lynch Syndrome Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2019
Multi-gene testing Submitted by Myriad Genetic Laboratories, Inc. on 10/28/2019
CRC Modifications Submitted by Myriad Genetic Laboratories, Inc. on 11/05/2020
Microsatellite Instability assays Submitted by Promega Corporation on 10/27/2021
Lynch syndrome and Polyposis Submitted by Quest Diagnostics, AliveAndKickn, FORCE, GenPath Oncology, Illumina Inc., Ambry Genetics and Myriad Genetic Laboratories, Inc. on 11/03/2021
Lynch syndrome Submitted by Invitae on 01/15/2022

Genetic: Colorectal/Colorectal Cancer Screening Panel

Epi proColon Submitted by Epigenomics Inc. on 09/25/2018

Head and Neck Cancers Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 04/06/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/13/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 04/16/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2018
Larotrectinib Submitted by Bayer HealthCare on 10/15/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 10/22/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 12/07/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 05/31/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 06/26/2019
Radiation Therapy Submitted by American Society for Radiation Oncology on 08/13/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 11/07/2019
Trastuzumab/pertuzumab Submitted by Genentech, Inc. on 02/18/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Radiation Therapy Submitted by American Society for Radiation Oncology on 05/28/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
NCCN Evidence Blocks Submitted by Merck & Co., Inc. on 06/18/2020
TMB Submitted by Foundation Medicine, Inc. on 06/22/2020
TMB Submitted by Foundation Medicine, Inc. on 09/15/2020
Next generation sequencing Submitted by Kura Oncology, Inc. on 04/29/2021
Tumor mutational burden Submitted by Illumina Inc. on 05/13/2021
Polymerized Cross-Linked Sucralfate (PCLS) Submitted by Translational Medicine Clinic & Research Center, LLC on 05/20/2021
Circulating cell-free DNA Submitted by Grail, Inc. on 05/28/2021
Lymphedema Submitted by Vanderbilt University School of Nursing on 05/28/2021
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. and AstraZeneca on 06/11/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/20/2021
The survival benefit of lymph node dissection in resected T1-2, cN0 supraglottic cancer: A population-based propensity score matching analysis Submitted by Sun Yat-sen University Cancer Center on 02/25/2022
Comparison of survival outcomes among patients with T1–2 cN0 oropharyngeal cancer treated with or without elective neck dissection Submitted by Sun Yat-sen University Cancer Center on 02/25/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Plasma-Based Comprehensive Genomic Profiling (CGP) Submitted by Guardant Health on 06/01/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022

Hematopoietic Cell Transplantation Panel

Abatacept Submitted by Bristol-Myers Squibb Company on 08/01/2019
Defibrotide sodium Submitted by Jazz Pharmaceuticals Inc. on 08/02/2019
Defibrotide sodium Submitted by Jazz Pharmaceuticals Inc. on 10/22/2020
Belumosudil Submitted by Kadmon Corporation LLC on 07/21/2021
Ruxolitinib Submitted by Incyte Corporation on 09/23/2021
Abatacept Submitted by Bristol-Myers Squibb Company on 12/14/2021

Hematopoietic Growth Factors Panel

Ferumoxytol Submitted by AMAG Pharmaceuticals on 04/10/2018
Epoetin alfa-epbx Submitted by Pfizer Inc. on 05/31/2018
Filgrastim-aafi Submitted by Pfizer Inc. on 08/09/2018
Pegfilgrastim-jmdb Submitted by Mylan N.V. on 10/24/2018
5-flurorouracil, oxaliplatin, leucovorin Submitted by Oncology Analytics, Inc. on 02/05/2019
Pegfilgrastim-cbqv Submitted by Coherus BioSciences on 02/11/2019
Filgrastim-sndz Submitted by Sandoz Inc. on 09/09/2019
Eflapegrastim-xnst Submitted by Spectrum Pharmaceuticals, Inc. on 08/31/2020
Granulocyte Colony Stimulating Factors (G-CSF) Submitted by The University of Arizona Cancer Center on 09/17/2020
Pegfilgrastim Submitted by Coherus BioSciences on 09/17/2020
Trilaciclib Submitted by G1 Therapeutics on 09/18/2020
Ferric Derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 09/21/2020
cabazitaxel Submitted by Sanofi on 01/29/2021
Trilaciclib Submitted by G1 Therapeutics on 02/12/2021
ferric derisomaltose Submitted by Pharmacosmos Therapeutics, Inc. on 03/09/2021
plinabulin_pegfilgrastin Submitted by BeyondSpring Pharmaceuticals, Inc. on 09/15/2021
Pegfilgrastim Submitted by on 09/28/2021
ferric carboxymaltose Submitted by American Regent on 03/24/2022
FOLFOX Submitted by eviCore Healthcare on 07/15/2022
eflapegrastim-xnst Submitted by Spectrum Pharmaceuticals, Inc. on 08/03/2022

Hepatobiliary Cancers Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/06/2018
Ramucirumab Submitted by Eli Lilly and Company on 06/22/2018
Cabozantinib Submitted by Exelixis Inc. on 07/13/2018
Lenvatinib Submitted by Eisai Inc. on 08/16/2018
Molecular testing Submitted by Foundation Medicine, Inc. on 08/23/2018
Lenvatinib Submitted by Eisai Inc. on 09/10/2018
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 10/30/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 11/12/2018
Regorafenib Submitted by Bayer HealthCare on 12/19/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 01/18/2019
Ramucirumab Submitted by Eli Lilly and Company on 05/16/2019
Larotrectinib Submitted by Bayer HealthCare on 05/28/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/11/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 06/14/2019
Entrectinib Submitted by Bayer HealthCare on 08/15/2019
Molecular Testing Submitted by Bayer HealthCare on 08/23/2019
Locoregional therapy Submitted by Society of Interventional Oncology on 08/26/2019
Cholangiocarcinoma Submitted by Foundation Medicine, Inc. on 09/24/2019
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 09/27/2019
Cholangiocarcinoma Submitted by Foundation Medicine, Inc. on 10/01/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/02/2019
Lenvatinib Submitted by Eisai Inc. on 11/12/2019
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 11/23/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 03/11/2020
Ivosidenib Submitted by Agios Pharmaceuticals, Inc. on 03/13/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pemigatinib Submitted by Incyte Corporation on 04/17/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Molecular testing Submitted by Foundation Medicine, Inc. on 05/14/2020
Lenvatinib Submitted by Eisai Inc. on 05/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Lenvatinib Submitted by Eisai Inc. on 08/12/2020
Radioembolization Submitted by Society of Interventional Oncology on 10/01/2020
Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/02/2020
Pralsetinib Submitted by Blueprint Medicines on 10/02/2020
Dabrafenib + Trametinib Submitted by Novartis Pharmaceuticals Corporation on 10/08/2020
Cabozantinib Submitted by Exelixis Inc. on 04/27/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/18/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/06/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 07/26/2021
Trastuzumab + pertuzumab Submitted by Genentech, Inc. on 08/11/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Galleri Submitted by Grail, Inc. on 09/07/2021
Ivosidenib Submitted by Servier Pharmaceuticals LLC on 09/08/2021
Radioembolization Submitted by Society of Interventional Oncology on 09/08/2021
Cabozantinib Submitted by Exelixis Inc. on 09/16/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 09/22/2021
Liposomal irinotecan Submitted by Ipsen Biopharmaceuticals, Inc. on 11/24/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/16/2021
Durvalumab + gemcitabine + cisplatin Submitted by AstraZeneca on 01/21/2022
Durvalumab Submitted by AstraZeneca on 01/21/2022
Pembrolizumab monotherapy Submitted by Merck & Co., Inc. on 01/21/2022
Cemiplimab Submitted by Sanofi and Regeneron Pharmaceuticals, Inc. on 02/17/2022
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 04/06/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
ASTRO Link Submitted by American Society for Radiation Oncology on 04/26/2022
Durvalumab + gemcitabine + cisplatin Submitted by AstraZeneca on 06/23/2022
T-DXd Submitted by AstraZeneca and Daiichi-Sankyo, Inc. on 07/05/2022
Durvalumab Submitted by AstraZeneca on 07/18/2022
Atezolizumab + Bevacizumab Submitted by Genentech, Inc. on 08/22/2022
Cabozantinib + Atezolizumab Submitted by Exelixis Inc. on 09/12/2022
Pembrolizumab + Lenvatinib Submitted by Merck & Co., Inc. on 09/14/2022
ASTRO Review Submitted by American Society for Radiation Oncology on 09/19/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Thermal Ablation Submitted by Society of Interventional Oncology on 09/30/2022
Pembrolizumab Submitted by eviCore Healthcare on 09/30/2022
Futibatinib Submitted by Taiho Oncology, Inc. on 10/03/2022
CGP Submitted by Guardant Health on 10/14/2022
CGP Submitted by Foundation Medicine, Inc. on 10/18/2022
Oncoguard Submitted by Community Liver Alliance on 10/20/2022
Tremelimumab-actl plus durvalumab Submitted by AstraZeneca on 10/24/2022
Ivosidenib Submitted by Servier Pharmaceuticals LLC on 11/15/2022
Futibatinib Submitted by Taiho Oncology, Inc. on 01/24/2023

Hodgkin Lymphoma Panel

Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/20/2018
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 04/15/2019
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 06/26/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 05/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 10/15/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/08/2021
Brentuximab vedotin + AVD Submitted by Seagen Inc on 07/22/2021
Brentuximab vedotin + AVD (BV+AVD) Submitted by Seagen Inc on 07/14/2022

Kidney Cancer Panel

Nivolumab Submitted by Bristol-Myers Squibb Company on 04/16/2018
Pazopanib Submitted by Novartis Pharmaceuticals Corporation on 05/29/2018
Atezolizumab Submitted by Genentech, Inc. on 06/25/2018
Cabozantinib Submitted by Exelixis Inc. on 06/26/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 07/02/2018
Avelumab + Axitinib Submitted by EMD Serono on 02/20/2019
T1a renal masses Submitted by Society of Interventional Oncology on 03/15/2019
Cabozantinib Submitted by Exelixis Inc. on 03/21/2019
Atezolizumab Submitted by Genentech, Inc. on 05/13/2019
Bevacizumab Submitted by Amgen Inc. on 07/19/2019
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020
Thermal Ablation Submitted by Society of Interventional Oncology on 03/02/2020
Lenvatinib Submitted by Eisai Inc. on 03/12/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 09/13/2020
Lenvatinib + Pembrolizumab Submitted by Eisai Inc. on 09/24/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 12/07/2020
Nivolumab + Cabozantinib Submitted by Bristol-Myers Squibb Company on 01/25/2021
Nivolumab + Cabozantinib Submitted by Exelixis Inc. on 01/25/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 02/04/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 02/11/2021
Lenvatinib + pembrolizumab Submitted by Eisai Inc. on 02/13/2021
Lenvatinib + Everolimus Submitted by Eisai Inc. on 02/13/2021
Nivolumab + Cabozantinib Submitted by Bristol-Myers Squibb Company on 03/04/2021
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 03/05/2021
Cabozantinib Submitted by Exelixis Inc. on 03/08/2021
Tivozanib Submitted by AVEO Oncology on 03/12/2021
Management of T1a renal masses Submitted by Society of Interventional Oncology on 03/31/2021
Cabozantinib Submitted by Exelixis Inc. on 04/15/2021
Tivozanib Submitted by AVEO Oncology on 04/16/2021
Tivozanib + Nivolumab Submitted by AVEO Oncology on 04/16/2021
Cabozantinib + Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/07/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/07/2021
Belzutifan Submitted by Merck & Co., Inc. on 08/19/2021
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 09/02/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 11/18/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 12/14/2021
Thermal Ablation Submitted by Society of Interventional Oncology on 02/11/2022
Tivozanib Submitted by AVEO Oncology on 03/08/2022
Tivozanib Submitted by AVEO Oncology on 03/08/2022
Tumor Testing Submitted by Ambry Genetics, GeneDx Inc, Myriad Genetic Laboratories Inc, Quest Diagnostics Laboratories and AliveAndKickn on 03/17/2022
Cabozantinib + Nivolumab Submitted by Exelixis Inc. on 03/21/2022
Treatment Clarification Submitted by Ambry Genetics, GeneDx Inc, Myriad Genetic Laboratories Inc, Quest Diagnostics Laboratories and AliveAndKickn on 08/24/2022

Lung Cancer Screening Panel

Percepta GSC Submitted by Veracyte, Inc. on 05/05/2022

Management of Immunotherapy-Related Toxicity Panel

Cetirizine hydrochloride Submitted by TerSera Therapeutics on 11/07/2019
Guardant360 Submitted by Guardant Health on 06/15/2020
Sargramostim Submitted by Partner Therapeutics on 06/17/2021
Cetirizine Submitted by Dr. Rex Garland, DO & Dr. Michael S. Blaiss, MD on 07/08/2021
nivolumab and relatlimab-rmbw Submitted by Bristol-Myers Squibb Company on 06/10/2022
Intravenous (IV) cetirizine hydrochloride Submitted by TerSera Therapeutics on 06/30/2022
mosunetuzumab Submitted by Genentech, Inc. on 12/23/2022

Melanoma Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 04/15/2018
Next-generation based testing Submitted by Illumina Inc. on 05/18/2018
Dabrafenib/Trametinib Submitted by Novartis Pharmaceuticals Corporation on 05/30/2018
Adhesive patch based non-invasive skin sampling tool Submitted by DermTech, Inc. on 05/31/2018
Encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor) Submitted by Array BioPharma Inc. on 06/20/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 11/29/2018
Larotrectinib Submitted by Bayer Healthcare Pharmaceuticals on 12/10/2018
Pigmented Lesion Assay (PLA) Submitted by DermTech, Inc. on 06/27/2019
DecisionDx-Melanoma Test Submitted by Castle Biosciences on 06/28/2019
Principles of Molecular Testing revisions Submitted by Myriad Genetic Laboratories, Inc. on 06/28/2019
Genetic testing for inherited melanoma risk Submitted by Myriad Genetic Laboratories, Inc. on 06/29/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 01/13/2020
Pembrolizumab dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 03/01/2020
Pembrolizumab dosing Submitted by Merck & Co., Inc. on 04/29/2020
Footnote and gene mutation listings Submitted by Myriad Genetic Laboratories, Inc. on 06/09/2020
Pembrolizumab weight-based dosing Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
GEP using DecisionDx-UM for Uveal Melanoma Submitted by Castle Biosciences on 06/15/2020
Pembrolizumab and low-dose ipilimumab for second- or subsequent line therapy Submitted by Merck & Co., Inc. on 06/16/2020
Pigmented lesion assay (PLA) Submitted by DermTech, Inc. on 06/16/2020
DecisionDx-Melanoma test (31-GEP) Submitted by Castle Biosciences on 06/17/2020
PLA Submitted by Dermatologic Surgery Center of Washington, LLC on 06/21/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 06/22/2020
Gene expression profiling (GEP) Submitted by Myriad Genetic Laboratories, Inc. on 06/22/2020
PLA Submitted by SUNY Downstate on 06/22/2020
PLA Submitted by University of Pittsburgh School of Medicine Department of Dermatology on 06/23/2020
PLA Submitted by Northwestern University Feinberg School of Medicine, Department of Dermatology on 06/23/2020
Pembrolizumab and low-dose ipilimumab for first-line Submitted by Merck & Co., Inc. on 07/21/2020
Atezolizumab in combination with cobimetinib and vemurafenib for Cutaneous Melanoma Submitted by Genentech, Inc. on 07/30/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 08/12/2020
Tumor mutation burden (TMB) measurement Submitted by Foundation Medicine, Inc. on 09/15/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 01/06/2021
Liquid biopsy-based DNA testing Submitted by Illumina Inc. on 05/28/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Nivolumab and Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/06/2021
Pembrolizumab and Lenvatinib Submitted by Merck & Co., Inc. on 06/07/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/07/2021
GEP Testing Submitted by Castle Biosciences on 06/11/2021
Adjuvant RT Submitted by American Society for Radiation Oncology on 06/11/2021
Pigmented lesion assay Submitted by DermTech, Inc. on 06/11/2021
Ipilimumab and sargramostim Submitted by Partner Therapeutics on 06/11/2021
Genomic patch testing Submitted by Georgetown University on 06/13/2021
Ripretinib for tumors with activating mutations of KIT (Cutaneous Melanoma) Submitted by Deciphera Pharmaceuticals, Inc. on 09/16/2021
Tebentafusp Submitted by Immunocore on 10/29/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 11/21/2021
Pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 12/02/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 12/03/2021
Nivolumab plus Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 12/09/2021
Nivolumab plus Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 12/10/2021
Pembrolizumab and lenvatinib (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 01/25/2022
Nivolumab and relatlimab-rmbw Submitted by Bristol-Myers Squibb Company on 03/18/2022
Nivolumab and relatlimab-rmbw (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 05/12/2022
Pembrolizumab (Cutaneous Melanoma) Submitted by Merck & Co., Inc. on 06/10/2022
Gene expression profiling (Melanoma: Cutaneous) Submitted by Castle Biosciences on 06/12/2022
Nivolumab and relatlimab-rmbw (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 06/15/2022
Nivolumab with Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 06/15/2022
Cutaneous Melanoma Submitted by Guardant Health on 06/15/2022
Ripretinib for tumors with activating mutations of KIT (Cutaneous Melanoma) Submitted by Deciphera Pharmaceuticals, Inc. on 06/28/2022
Ipilimumab (Cutaneous Melanoma) Submitted by Bristol-Myers Squibb Company on 10/11/2022

Multiple Myeloma/Systemic Light Chain Amyloidosis/Waldenström Macroglobulinemia Panel

Pomalidomide + Dexamethasone Submitted by Celgene Corporation on 03/30/2018
Lenalidomide Submitted by Celgene Corporation on 04/12/2018
MMprofiler Submitted by SkylineDX on 04/18/2018
Ixazomib Submitted by Takeda Oncology on 04/23/2018
Ixazomib ICd Submitted by Takeda Oncology on 04/23/2018
Ixazomib Maintenance Submitted by Takeda Oncology on 04/23/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 05/09/2018
Minimal Residual Disease (MRD) analysis Submitted by Adaptive Biotechnologies on 05/10/2018
Daratumumab + Carfilzomib + Dexamethasone Submitted by Janssen Biotech, Inc. on 06/07/2018
Acalabrutinib Submitted by AstraZeneca on 06/11/2018
Ibrutinib Submitted by Pharmacyclics, LLC on 06/20/2018
Ixazomib Submitted by Takeda Oncology on 12/02/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 12/06/2018
Ibrutinib Submitted by Pharmacyclics, LLC on 12/20/2018
Daratumumab Submitted by Janssen Biotech, Inc. on 02/12/2019
Lenalidomide Submitted by Celgene Corporation on 03/15/2019
Ixazomib Submitted by Takeda Oncology on 03/21/2019
clonoSEQ® assay Submitted by Adaptive Biotechnologies on 04/26/2019
SKY92 high risk gene expression signature Submitted by SkylineDX on 04/30/2019
SKY92 high risk gene expression signature Submitted by SkylineDX on 04/30/2019
Daratumumab Submitted by Janssen Biotech, Inc. on 05/09/2019
Pomalidomide Submitted by Celgene Corporation on 05/14/2019
Daratumumab Submitted by Janssen Biotech, Inc. on 06/07/2019
Selinexor Submitted by Karyopharm Therapeutics on 07/22/2019
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 09/27/2019
Isatuximab Submitted by Sanofi on 12/09/2019
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 12/20/2019
Lenalidomide Submitted by Bristol-Myers Squibb Company on 01/16/2020
Isatuximab Submitted by Sanofi on 03/02/2020
Dexamethasone Submitted by Acrotech Biopharma LLC on 03/18/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies on 03/27/2020
Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020
Ixazomib + Lenalidomide Submitted by Takeda Oncology on 03/27/2020
Ixazomib Submitted by Takeda Oncology on 03/27/2020
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 05/12/2020
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 06/16/2020
Zanubrutinib Submitted by BeiGene, Ltd. on 07/31/2020
Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 08/05/2020
Carfilzomib Submitted by Amgen Inc. on 08/21/2020
Selinexor Submitted by Karyopharm Therapeutics on 11/12/2020
Ibrutinib Submitted by Pharmacyclics, LLC on 12/07/2020
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 02/01/2021
Melphalan flufenamide Submitted by Oncopeptides, Inc. on 03/01/2021
Ixazomib Submitted by Takeda Oncology on 03/24/2021
MRD assessment Submitted by Adaptive Biotechnologies on 03/25/2021
Idecabtagene Vicleucel Submitted by Bristol-Myers Squibb Company on 03/26/2021
Isatuximab Submitted by Sanofi on 03/31/2021
Selinexor + Dexamethasone Submitted by Karyopharm Therapeutics on 05/03/2021
Carfilzomib Submitted by Amgen Inc. on 05/18/2021
Pomalidomide Submitted by Bristol-Myers Squibb Company on 07/07/2021
Lenalidomide Submitted by Bristol-Myers Squibb Company on 07/15/2021
Daratumumab and Hyaluronidase-fihj Submitted by Janssen Scientific Affairs, LLC on 07/19/2021
Daratumumab Submitted by Janssen Scientific Affairs, LLC on 08/26/2021
elotuzumab Submitted by Bristol-Myers Squibb Company on 09/09/2021
Denosumab Submitted by Amgen Inc. on 09/22/2021
Selinexor_carfilzomib_dexamethasone Submitted by Karyopharm Therapeutics on 11/23/2021
blenrep Submitted by GlaxoSmithKline on 12/17/2021
isatuximab Submitted by Sanofi on 01/03/2022
cilta-cel Submitted by Janssen Biotech, Inc. on 03/02/2022
Gene expression profiling Submitted by SkylineDX on 03/30/2022
Belantamab mafodotin-blmf Submitted by GlaxoSmithKline on 11/22/2022

Myelodysplastic Syndromes Panel

Patient evaluation Submitted by Foundation Medicine, Inc. on 03/26/2018
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 01/09/2020
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 04/10/2020
Decitabine and Cedazuridine Submitted by Taiho Oncology, Inc. on 07/10/2020
Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 03/12/2021
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 04/01/2021
Luspatercept-aamt Submitted by Bristol-Myers Squibb Company on 12/13/2021

Myeloproliferative Neoplasms Panel

Fedratinib Submitted by Celgene Corporation on 06/27/2019
Fedratinib Submitted by Celgene Corporation on 08/16/2019
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 07/16/2020
Avapritinib Submitted by Blueprint Medicines on 06/17/2021
Pacritinib Submitted by CTI BioPharma Corp. on 07/08/2021
Approval of Ropeginterferon alfa-2b-njft for Polycythemia Vera (PV) Submitted by PharmaEssentia Corporation on 11/14/2021
Submission request to review pemigatinib in the MLNE Guidelines Submitted by Incyte Corporation on 08/01/2022

Neuroendocrine Tumors Panel

HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 07/10/2018
HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 09/07/2018
HSA iobenguane I 131 Submitted by Progenics Pharmaceuticals Inc. on 09/11/2018
Avelumab Submitted by EMD Serono on 03/05/2019
Telotristat ethyl Submitted by Lexicon Pharmaceuticals, Inc. on 05/06/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Copper Cu 64 dotatate Submitted by Curium on 10/07/2019
Liver-Directed Therapy Submitted by Society of Interventional Oncology on 10/15/2019
Nivolumab/Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
SSR PET tracer options Submitted by Curium on 09/03/2020
Pralsetinib Submitted by Blueprint Medicines on 09/10/2020
TMB and pembrolizumab Submitted by Foundation Medicine, Inc. on 09/18/2020
Liver Directed Therapy Submitted by Society of Interventional Oncology on 10/08/2020
Principles of Hormone Control Submitted by TerSera Therapeutics on 10/27/2020
cabozantinib Submitted by Exelixis Inc. on 06/09/2021
lenvatinib Submitted by Eisai Inc. on 06/25/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Belzutifan Submitted by Merck & Co., Inc. on 08/19/2021
PRRT Lu DOTATATE Submitted by Novartis Pharmaceuticals Corporation on 09/22/2021
Telotristat ethyl Submitted by TerSera Therapeutics on 10/28/2021

Non-Melanoma Skin Cancer Panel

Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 06/15/2018
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/28/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 09/29/2019
Pembrolizumab for Basal Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Merkel Cell Carcinoma Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 03/20/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 03/26/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/25/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 06/25/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 07/08/2020
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 09/14/2020
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/10/2021
Sonidegib Submitted by Sunesis Pharmaceuticals, Inc. on 02/26/2021
Avelumab Submitted by Pfizer Inc. on 04/08/2021
Pembrolizumab for Squamous Cell Skin Cancer Submitted by Merck & Co., Inc. on 07/13/2021
Radiation Therapy Submitted by American Society for Radiation Oncology on 03/29/2022
40-GEP Submitted by Castle Biosciences on 04/08/2022
IGSRT Submitted by SkinCure Oncology on 04/13/2022
40-GEP Submitted by University of Rochester Medical Center, Department of Dermatology on 04/19/2022
ASTRO Link Submitted by American Society for Radiation Oncology on 04/26/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Cemiplimab-rwlc Submitted by Regeneron Pharmaceuticals, Inc. on 10/03/2022
40-GEP Submitted by Castle Biosciences on 10/18/2022

Non-Small Cell Lung Cancer/Mesothelioma/Thymomas and Thymic Carcinomas Panel

Next-generation sequencing Submitted by Illumina Inc. on 04/11/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 04/16/2018
Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/16/2018
Osimertinib Submitted by AstraZeneca on 04/18/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 05/02/2018
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/04/2018
Gefitinib Submitted by AstraZeneca on 05/14/2018
Tumor Mutational Burden Submitted by Foundation Medicine, Inc. on 05/25/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 06/03/2018
Durvalumab Submitted by AstraZeneca on 06/03/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/03/2018
Atezolizumab and Alectinib Submitted by Genentech, Inc. on 06/04/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2018
Osimertinib Submitted by AstraZeneca on 06/06/2018
Avelumab Submitted by EMD Serono on 06/11/2018
Dabrafenib and Trametinib Submitted by Novartis Pharmaceuticals Corporation on 06/15/2018
Afatinib Submitted by Boehringer Ingelheim on 07/24/2018
Guardant360 Submitted by Guardant Health on 09/23/2018
Guardant360 Submitted by Guardant Health on 09/23/2018
Atezolizumab Submitted by Genentech, Inc. on 09/24/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 09/27/2018
Pembrolizumab Submitted by Merck & Co., Inc. on 09/28/2018
Dacomitinib Submitted by Pfizer Inc. on 10/01/2018
Brigatinib Submitted by Takeda Oncology on 10/02/2018
Brigatinib Submitted by Takeda Oncology on 10/02/2018
Afatinib Addendum Submitted by Boehringer Ingelheim on 10/11/2018
Atezolizumab Submitted by Genentech, Inc. on 10/23/2018
Durvalumab Submitted by AstraZeneca on 10/25/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 10/26/2018
Lorlatinib Submitted by Pfizer Inc. on 11/02/2018
Larotrectinib Submitted by Bayer HealthCare on 12/10/2018
Osimertinib Submitted by AstraZeneca on 01/17/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 02/13/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 04/12/2019
Durvalumab Submitted by AstraZeneca on 06/03/2019
Brigatinib Submitted by Takeda Oncology on 06/06/2019
Brigatinib Post Crizotinib Submitted by Takeda Oncology on 06/10/2019
Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 06/21/2019
Bevacizumab-awwb Submitted by Amgen Inc. on 07/19/2019
Liquid Biopsy Submitted by AstraZeneca on 08/07/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 09/28/2019
Atezolizumab Submitted by Genentech, Inc. on 09/30/2019
Ramucirumab Submitted by Eli Lilly and Company on 10/29/2019
Atezolizumab Submitted by Genentech, Inc. on 12/03/2019
Guardant360 Submitted by Guardant Health on 01/22/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Selpercatinib Submitted by Eli Lilly and Company on 03/27/2020
Guardant360 Submitted by Guardant Health on 03/27/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/13/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 05/06/2020
Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020
Durvalumab Submitted by AstraZeneca on 05/14/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/15/2020
Atezolizumab Submitted by Genentech, Inc. on 05/20/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/26/2020
Brigatinib Submitted by Takeda Oncology on 05/26/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/29/2020
Osimertinib Submitted by AstraZeneca on 05/31/2020
Pembrolizumab Submitted by Value in Cancer Care Consortium (Vi3C) on 06/10/2020
T-DXd Submitted by Daiichi-Sankyo, Inc. on 06/15/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/22/2020
Key Recommendations Submitted by American Society for Radiation Oncology on 06/23/2020
Lenvatinib Submitted by Eisai Inc. on 06/23/2020
Comprehensive genomic profiling Submitted by Foundation Medicine, Inc. on 06/30/2020
Image-Guided Thermal Ablation (IGTA) Submitted by Society of Interventional Oncology on 07/01/2020
Guardant360 Submitted by Guardant Health on 07/02/2020
Tumor Treating Fields Submitted by Novocure on 07/03/2020
Bevacizumab Submitted by Genentech, Inc. on 07/06/2020
Brigatinib Submitted by Takeda Oncology on 07/07/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 07/08/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 07/13/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 08/08/2020
Pralsetinib Submitted by Blueprint Medicines on 09/08/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020
Osimertinib Submitted by AstraZeneca on 09/19/2020
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2020
Atezolizumab Submitted by Genentech, Inc. on 10/01/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 10/02/2020
Capmatinib Submitted by Novartis Pharmaceuticals Corporation on 11/04/2020
Lorlatinib Submitted by Pfizer Inc. on 11/19/2020
Durvalumab Submitted by AstraZeneca on 11/20/2020
Osimertinib Submitted by AstraZeneca on 12/21/2020
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 01/18/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 01/21/2021
Integrated Classifier Submitted by Medical University of South Carolina on 01/27/2021
Tepotinib Submitted by EMD Serono on 02/04/2021
Atezolizumab Submitted by Genentech, Inc. on 02/09/2021
Cemiplimab Submitted by Regeneron Pharmaceuticals, Inc. on 02/16/2021
Osimertinib Submitted by AstraZeneca on 03/09/2021
NGS Submitted by AstraZeneca on 03/10/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/10/2021
Sotorasib Submitted by Amgen Inc. on 04/22/2021
Albumin-bound paclitaxel Submitted by Bristol-Myers Squibb Company on 05/14/2021
Amivantamab-vmjw Submitted by Janssen Biotech, Inc. on 05/24/2021
Afatinib Submitted by Boehringer Ingelheim on 05/26/2021
CGP Submitted by Illumina Inc. on 05/26/2021
Nivolumab_ipilimumab Submitted by Bristol-Myers Squibb Company on 06/04/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/04/2021
DetermaRx Submitted by Oncocyte on 06/04/2021
Atezolizumab Submitted by Genentech, Inc. on 06/06/2021
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/06/2021
CGP Submitted by Foundation Medicine, Inc. on 06/09/2021
Mobocertinib Submitted by Takeda Oncology on 06/10/2021
CGP Submitted by Guardant Health on 06/10/2021
Tepotinib Submitted by EMD Serono on 06/10/2021
Tepotinib METAmp Submitted by EMD Serono on 06/10/2021
Genetics Submitted by Myriad Genetic Laboratories, Inc. on 06/16/2021
Selpercatinib Submitted by Eli Lilly and Company on 06/17/2021
IGTA Submitted by Society of Interventional Oncology on 06/18/2021
Mobocertinib Submitted by Takeda Oncology on 09/16/2021
Atezolizumab Submitted by Genentech, Inc. on 09/20/2021
Osimertinib Submitted by AstraZeneca on 10/12/2021
Atezolizumab Submitted by Genentech, Inc. on 10/15/2021
Durvalumab Submitted by AstraZeneca on 10/19/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 11/12/2021
Atezoliumab Submitted by Genentech, Inc. on 12/13/2021
Atezoliumab Submitted by Genentech, Inc. on 01/12/2022
Neoadjuvant Therapy Submitted by Champalimaud Foundation on 02/16/2022
Nivolumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 03/04/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Nivolumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 04/11/2022
Sotorasib Submitted by Amgen Inc. on 05/11/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 05/16/2022
Pembrolizumab + Ramucirumab Submitted by Merck & Co., Inc. on 06/03/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 06/06/2022
Integrated Classifier Submitted by Biodesix on 06/07/2022
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 06/08/2022
Durvalumab Submitted by AstraZeneca on 06/08/2022
Nivolumab + Ipilimumab + Chemotherapy Submitted by Bristol-Myers Squibb Company on 06/08/2022
Molecular Profiling Submitted by Foundation Medicine, Inc. on 06/09/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 06/09/2022
Comprehensive Genomic Profiling Submitted by Guardant Health on 06/16/2022
Broad Molecular Profiling Submitted by Eli Lilly and Company on 06/17/2022
Dostarlimab-gxly Submitted by GlaxoSmithKline on 06/28/2022
Fam-trastuzumab deruxtecan-nxki Submitted by Daiichi-Sankyo, Inc. and AstraZeneca on 08/12/2022
Adagrasib Submitted by Mirati Therapeutics, Inc. on 10/31/2022
Cemiplimab-rwlc Submitted by Regeneron Pharmaceuticals, Inc. on 11/11/2022
Durvalumab + Tremelimumab-actl Submitted by AstraZeneca on 11/14/2022
Pembrolizumab Submitted by Merck & Co., Inc. on 01/27/2023

Occult Primary Panel

Vitrakvi Submitted by Bayer HealthCare on 12/10/2018
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/19/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 09/15/2020
Galleri Submitted by Grail, Inc. on 05/11/2021
TMB Submitted by Foundation Medicine, Inc. on 05/13/2021
TMB Submitted by Illumina Inc. on 05/13/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
Evaluation and management Submitted by Foundation Medicine, Inc. on 03/22/2022
Nivolumab_ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022

Older Adult Oncology Panel

Cetirizine hydrochloride Submitted by TerSera Therapeutics on 09/11/2020
Guardant360 CDx Submitted by Guardant Health on 09/30/2020
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 03/05/2021
Cetirizine Submitted by TerSera Therapeutics on 03/05/2021
IV Cetirizine Submitted by Dr. Rex Garland, DO & Dr. Michael S. Blaiss, MD on 10/05/2021

Ovarian Cancer Panel

Bevacizumab Submitted by Genentech, Inc. on 06/13/2018
Niraparib Submitted by TESARO, Inc. on 06/25/2018
PARP inhibitor maintenance Submitted by TESARO, Inc. on 10/10/2018
Niraparib Submitted by TESARO, Inc. on 10/12/2018
Olaparib Submitted by AstraZeneca on 10/22/2018
Olaparib Submitted by AstraZeneca on 06/03/2019
Olaparib Submitted by AstraZeneca on 07/02/2019
Paxman Scalp Cooling System Submitted by Paxman Coolers Limited on 07/26/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
OVA1/Multivariate Index Assay Submitted by Vermillion, Inc. on 09/18/2019
Bevacizumab-awwb Submitted by United Healthcare on 09/26/2019
Nirabarib Submitted by GlaxoSmithKline on 09/30/2019
Olaparib Submitted by AstraZeneca on 10/01/2019
Molecular testing Submitted by Foundation Medicine, Inc. on 10/02/2019
Trabectedin Submitted by Janssen Scientific Affairs, LLC on 02/04/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Olaparib Submitted by Clovis Oncology on 05/15/2020
Olaparib Submitted by AstraZeneca on 05/15/2020
Niraparib Submitted by GlaxoSmithKline on 05/19/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 06/04/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
myChoice CDx Submitted by Myriad Genetic Laboratories, Inc. on 09/08/2020
OVA1 Multivariate Index Assay Submitted by ASPiRA Women’s Health on 09/10/2020
Guardant360 Submitted by Guardant Health on 09/11/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals Inc. on 09/16/2020
TMB Submitted by Foundation Medicine, Inc. on 09/18/2020
CDx genomic profiling test Submitted by Foundation Medicine, Inc. on 11/06/2020
Selinexor Submitted by Karyopharm Therapeutics on 01/21/2021
Niraparib + Bevacizumab Submitted by GlaxoSmithKline on 03/22/2021
Surveillance Submitted by Sunnybrook Health Sciences Centre on 04/08/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/18/2021
Olaparib Submitted by AstraZeneca on 08/06/2021
Dostarlimab-gxly Submitted by GlaxoSmithKline on 08/17/2021
HR Deficiency Submitted by Myriad Genetic Laboratories, Inc. on 09/01/2021
Comprehensive Molecular Testing Submitted by Foundation Medicine, Inc. on 09/09/2021
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 10/07/2021
Olaparib Submitted by AstraZeneca on 10/12/2021
Nivolumab + ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Rucaparib Submitted by Clovis Oncology on 06/09/2022
Niraparib + bevacizumab Submitted by GlaxoSmithKline on 06/14/2022
Niraparib Submitted by GlaxoSmithKline on 09/15/2022
Niraparib Submitted by GlaxoSmithKline on 09/16/2022
Cetirizine hydrochloride Submitted by TerSera Therapeutics on 09/16/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
HR Deficiency Submitted by Myriad Genetic Laboratories, Inc. on 09/29/2022
ctDNA Submitted by Foundation Medicine, Inc. on 09/29/2022
Pembrolizumab Submitted by eviCore Healthcare on 09/30/2022
Guardant360 Submitted by Guardant Health on 09/30/2022
Mirvetuximab soravtansine Submitted by ImmunoGen, Inc. on 10/03/2022
Mirvetuximab soravtansine + bevacizumab Submitted by ImmunoGen, Inc. on 10/03/2022
Olaparib (+/- bevacizumab) Submitted by AstraZeneca on 10/14/2022

Palliative Care Panel

Interventional Radiologist (IR) consultation Submitted by Society of Interventional Oncology on 07/13/2020

Pancreatic Adenocarcinoma Panel

Comprehensive Genomic Profiling Submitted by Foundation Medicine, Inc. on 07/03/2018
Olaparib Submitted by AstraZeneca on 06/02/2019
Olaparib Submitted by AstraZeneca on 06/02/2019
Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 06/25/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Evidence Blocks Submitted by United Healthcare on 02/24/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Germline testing Submitted by Myriad Genetic Laboratories, Inc. on 06/08/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 06/12/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Gemcitabine/albumin-bound paclitaxel/cisplatin Submitted by Johns Hopkins Medical Insitutions on 06/18/2020
TMB Submitted by Foundation Medicine, Inc. on 06/22/2020
TMB Submitted by Foundation Medicine, Inc. on 09/15/2020
Pralsetinib Submitted by Blueprint Medicines on 09/30/2020
Multi-gene panel testing Submitted by Myriad Genetic Laboratories, Inc. on 05/20/2021
Rucaparib Submitted by Clovis Oncology on 06/03/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/18/2021
Methylation-based blood test Submitted by Grail, Inc. on 06/21/2021

Pediatric Acute Lymphoblastic Leukemia Panel

Blinatumomab Submitted by Amgen Inc. on 02/11/2020
ClonoSEQ® Assay Submitted by Adaptive Biotechnologies on 05/22/2020
clonoSEQ Submitted by Adaptive Biotechnologies on 10/26/2020
MRD Testing Submitted by Adaptive Biotechnologies on 05/19/2021
Asparaginase erwinia chrysanthemi (recombinant) Submitted by Jazz Pharmaceuticals Inc. on 07/02/2021
asparaginase erwinia chrysanthemi Submitted by Jazz Pharmaceuticals Inc. on 04/08/2022
glucarpidase and MTXPK tool Submitted by BTG International on 05/19/2022

Pediatric Hodgkin Lymphoma Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 10/15/2020
brentuximab vedotin + doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (BV-AVE-PC) Submitted by Seagen Inc on 12/07/2022

Prevention and Treatment of Cancer-Related Infections Panel

Meropenem and Vaborbactam Submitted by Melinta Therapeutics, Inc. on 10/01/2018
Bezlotoxumab Submitted by Merck & Co., Inc. on 05/29/2019
Temp Traq Submitted by Blue Spark Technologies on 06/26/2019
ASCENIV® Submitted by ADMA Biologics on 09/25/2020

Prostate Cancer Early Detection Panel

EPI biomarker Submitted by Exosome Diagnostics, Inc. on 04/23/2018
3-gene expression assay Submitted by Exosome Diagnostics, Inc. on 08/13/2018
EPI test Submitted by Exosome Diagnostics, Inc. on 09/20/2018
SelectMDx Submitted by MDxHealth on 10/02/2018
SelectMDx Submitted by MDxHealth on 06/03/2019
Germline Genetic Testing Submitted by Myriad Genetic Laboratories, Inc. on 09/18/2020
miR Scientific Sentinel Prostate Cancer Test Platform Submitted by Columbia University Medical Center on 09/23/2020
miR Scientific Sentinel™ Prostate Cancer Test Platform Submitted by miR Scientific on 09/29/2020
ExactVu 29MHz Micro-Ultrasound system Submitted by Exact Imaging Inc. on 11/10/2020
IsoPSA Submitted by Cleveland Diagnostics, Inc. on 09/15/2021
Stockholm3 Submitted by Karolinska Institutet and A3P Biomedical AB on 09/19/2021
miR Scientific Sentinel Submitted by Vanderbilt University Medical Center on 09/20/2021
miR Scientific Sentinel_2 Submitted by Vanderbilt University Medical Center on 09/20/2021
ExoDx Prostate Test Submitted by ExosomeDx on 10/03/2022

Prostate Cancer Panel

Apalutamide Submitted by Janssen Scientific Affairs, LLC on 05/23/2018
Genomic classifier Submitted by GenomeDx Biosciences Inc. on 06/01/2018
Fluciclovine Submitted by Blue Earth Diagnostics on 06/06/2018
AR-V7 Submitted by Epic Sciences, Inc. on 06/07/2018
Prolaris Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2018
Prolaris Post‐RP Submitted by Myriad Genetic Laboratories, Inc. on 06/07/2018
Denosumab and Zolendronic Acid Submitted by Prostate Health Education Network, Inc. on 06/20/2018
Enzalutamide Submitted by Astellas Pharma Inc. on 07/13/2018
GnRH antagonist degarelix Submitted by Ferring Pharmaceuticals on 10/11/2018
Abiraterone Acetate Submitted by Value in Cancer Care Consortium (Vi3C) on 10/14/2018
Sipuleucel-T Submitted by Dendreon Corporation on 02/19/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 03/15/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 04/09/2019
Tumor Tissue-Based Molecular Assay Submitted by Decipher Biosciences Inc. on 06/01/2019
Apalutamide Submitted by Janssen Scientific Affairs, LLC on 06/04/2019
Molecular and biomarker analysis of tumor Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019
Genetic Testing in Active Surveillance Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019
Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 06/04/2019
PCR-based Microsatellite Instability (MSI) assays Submitted by Promega Corporation on 06/06/2019
Abiraterone Acetate Submitted by Janssen Scientific Affairs, LLC on 06/11/2019
Enzalutamide Submitted by Astellas Pharma Inc. on 07/29/2019
Olaparib Submitted by AstraZeneca on 09/30/2019
Cabazitaxel Submitted by Sanofi on 10/08/2019
Atezolizumab Submitted by Genentech, Inc. on 11/27/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Cabazitaxel Submitted by Sanofi on 03/23/2020
Guardant360 Submitted by Guardant Health on 04/22/2020
Molecular/Biomarker Analysis Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020
Genetic Testing and Risk Stratification Submitted by Myriad Genetic Laboratories, Inc. on 04/23/2020
Genomic profiling Submitted by Foundation Medicine, Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Cabazitaxel Submitted by Sanofi on 05/04/2020
Darolutamide Submitted by Bayer HealthCare on 05/11/2020
Rucaparib Submitted by Clovis Oncology on 05/15/2020
Rucaparib Submitted by Clovis Oncology on 05/15/2020
Laser Focal Therapy Submitted by Halo Diagnostics on 06/06/2020
CGP Submitted by Foundation Medicine, Inc. on 08/28/2020
TMB Submitted by Foundation Medicine, Inc. on 09/15/2020
Plasma ctDNA test Submitted by AstraZeneca on 12/09/2020
Relugolix Submitted by Myovant Sciences, Inc. on 12/23/2020
cabazitaxel Submitted by Sanofi on 01/29/2021
PSMA PET_CT Submitted by UCLA on 02/24/2021
apalutamide Submitted by Janssen Scientific Affairs, LLC on 02/25/2021
relugolix Submitted by Myovant Sciences, Inc. on 03/19/2021
Talazoparib Submitted by Pfizer Inc. on 03/23/2021
CGP Submitted by Guardant Health on 04/09/2021
Germline Testing Submitted by Myriad Genetic Laboratories, Inc. on 04/13/2021
Molecular Marker Submitted by Myriad Genetic Laboratories, Inc. on 04/13/2021
Genomic Profiling Submitted by Foundation Medicine, Inc. on 04/14/2021
Oncotype DX GPS Submitted by Exact Sciences Inc. on 04/15/2021
Oncotype DX GPS Submitted by Exact Sciences Inc. on 04/15/2021
Decipher Submitted by Decipher Biosciences Inc. on 04/16/2021
relugolix Submitted by TerSera Therapeutics on 04/26/2021
fluciclovine Submitted by Blue Earth Diagnostics on 05/06/2021
Cabazitaxel Submitted by Sanofi on 06/15/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2021
piflufolastat F 18 Submitted by Lantheus Holdings on 06/28/2021
olaparib plus abiraterone Submitted by AstraZeneca on 02/17/2022
Darolutamide Submitted by Bayer HealthCare on 02/18/2022
Pluvicto Submitted by Novartis Pharmaceuticals Corporation on 03/23/2022
Oncotype DX Submitted by Exact Sciences Inc. on 03/30/2022
Decipher Submitted by Veracyte, Inc. on 04/01/2022
Genomic Profiling Submitted by Foundation Medicine, Inc. on 04/01/2022
miR Sentinel Submitted by miR Scientific on 04/01/2022
Talazoparib Submitted by Pfizer Inc. on 04/01/2022
ATM germline Submitted by Ambry Genetics on 04/05/2022
molecular and biomarker analysis Submitted by Myriad Genetic Laboratories, Inc. on 04/08/2022
nivolumab ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
olaparib plus abiraterone Submitted by AstraZeneca on 06/03/2022

Small Cell Lung Cancer Panel

Pembrolizumab Submitted by Merck & Co., Inc. on 06/07/2018
Atezolizumab Submitted by Genentech, Inc. on 09/25/2018
Nivolumab Submitted by Bristol-Myers Squibb Company on 04/11/2019
Entrectinib Submitted by Genentech, Inc. on 08/15/2019
Durvalumab Submitted by AstraZeneca on 09/19/2019
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/04/2019
Atezolizumab Submitted by Genentech, Inc. on 12/23/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Lurbinectedin Submitted by Jazz Pharmaceuticals Inc. on 06/15/2020
Nivolumab Submitted by Bristol-Myers Squibb Company on 12/29/2020
Trilaciclib Submitted by G1 Therapeutics on 02/12/2021
Atezolizumab Submitted by Genentech, Inc. on 03/16/2021
Pembrolizumab Submitted by Merck & Co., Inc. on 03/31/2021
Radiation Therapy Submitted by American Society for Radiation Oncology on 03/04/2022
Nivolumab in combination with ipilimumab for patients with advanced or metastatic tTMB-H solid tumors Submitted by Bristol-Myers Squibb Company on 04/11/2022

Soft Tissue Sarcoma Panel

Diagnostic Algortihm Submitted by The Life Raft Group on 05/21/2019
ENLIVEN, pexidartinib Submitted by Daiichi-Sankyo, Inc. on 08/05/2019
Entrectinib Submitted by Genentech, Inc. on 08/16/2019
Avapritinib Submitted by Blueprint Medicines on 01/07/2020
Avapritinib Submitted by Blueprint Medicines on 01/09/2020
Tazemetostat Submitted by Epizyme Inc. on 01/23/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/11/2020
Treatment Algorithm Submitted by The Desmoid Tumor Research Foundation on 03/17/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 03/20/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 05/18/2020
Footnotes Submitted by Society of Interventional Oncology on 06/08/2020
Cabozantinib Submitted by Exelixis Inc. on 06/10/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Comprehensive genomic profiling (CGP) Submitted by Foundation Medicine, Inc. on 06/17/2020
Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 06/19/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/23/2020
Ripretinib Submitted by Deciphera Pharmaceuticals, Inc. on 08/17/2020
Submission request for review of selinexor in soft tissue sarcoma. Submitted by American Society for Radiation Oncology and Karyopharm Therapeutics on 04/29/2021
Update principles of Ancillary Techniques to include statement regarding molecular genetic testing. Submitted by Foundation Medicine, Inc. on 05/14/2021
Submission for 2021 NCCN Soft Tissue Sarcoma Guideline gaps relative to radiation therapy Submitted by American Society for Radiation Oncology on 06/11/2021
Request for addition of regorafenib an open-label single-arm phase II study for the treatment of angiosarcoma. Submitted by Bayer HealthCare on 08/02/2021
Update to Submission for Ripretinib Dose Escalation to 150 mg Twice Daily (BID) Submitted by Deciphera Pharmaceuticals, Inc. on 08/16/2021
Request the inclusion of pembrolizumab in combination with axitinib as a treatment option for patients with advanced sarcomas including alveolar soft part sarcoma. Submitted by Merck & Co., Inc. on 08/27/2021
Submission for FYARRO (sirolimus protein-bound particles for injectable suspension) (albumin-bound) Submitted by Aadi Bioscience on 11/26/2021
Ponatinib Submitted by Takeda Oncology on 04/08/2022
Request to include nivolumab in combination with ipilimumab as a treatment option for patients with tissue TMB-H (tTMB-H) Submitted by Bristol-Myers Squibb Company on 04/11/2022
Selinexor Submitted by Karyopharm Therapeutics on 04/11/2022
Atezolizumab for ASPS Submitted by Genentech, Inc. on 06/15/2022
Crizotinib Submitted by Pfizer Inc. on 07/14/2022
Request hepatic artery embolization Submitted by Society of Interventional Oncology on 08/11/2022
Ripretinib as a second line treatment option Submitted by Deciphera Pharmaceuticals, Inc. on 08/11/2022
Update embolization procedure and consider additional footnotes Submitted by Society of Interventional Oncology on 08/11/2022
Update statement regarding molecular genetic testing Submitted by Foundation Medicine, Inc. on 08/16/2022
Selpercatinib Submitted by Eli Lilly and Company on 09/21/2022
Request to include lenvatinib in combination with eribulin as a treatment option Submitted by Eisai Inc. on 10/17/2022

Survivorship Panel

Lymphedema symptom assessment Submitted by Vanderbilt University School of Nursing on 10/31/2018
Genetic risk assessment and testing Submitted by Myriad Genetic Laboratories, Inc. on 10/29/2019
Head and neck lymphedema Submitted by Vanderbilt University School of Nursing on 11/09/2020
Pneumatic compression for lymphedema Submitted by Vanderbilt University School of Nursing on 11/09/2020
Intermittent fasting data Submitted by Moffitt Cancer Center/ University of South Florida on 01/15/2021
Web-based Survivorship Care Plan Submitted by OncoLink on 08/04/2021
Zoster Vaccine Recombinant, Adjuvanted [RZV]) Submitted by GlaxoSmithKline on 10/23/2021

T-Cell/Primary Cutaneous Lymphomas Panel

Next-generation sequencing (NGS) Submitted by Illumina Inc. on 05/07/2018
Next generation sequence based analysis Submitted by Adaptive Biotechnologies on 05/18/2018
Mogamulizumab Submitted by Kyowa Kirin, Inc. on 07/30/2018
Brentuximab vedotin Submitted by Seattle Genetics, Inc. on 11/21/2018
Duvelisib Submitted by Verastem, Inc. on 05/17/2019
Duvelisib + Romidepsin Submitted by Verastem, Inc. on 05/17/2019
Next-generation sequencing (NGS) Submitted by Adaptive Biotechnologies on 06/28/2019
Pembrolizumab Submitted by Merck & Co., Inc. on 02/03/2020
Duvelisib Submitted by Verastem, Inc. on 06/11/2020
Leucovorin Submitted by Acrotech Biopharma LLC on 06/12/2020
ENKTL Submitted by Sun Yat-sen University Cancer Center on 06/14/2020
clonoSEQ® Assay Submitted by Adaptive Biotechnologies on 06/19/2020
Alectinib Submitted by Genentech, Inc. on 07/19/2021
Romidepsin Submitted by Bristol-Myers Squibb Company on 12/03/2021

Testicular Cancer Panel

BEP x 3 Submitted by Lawrence H. Einhorn, MD on 03/05/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 04/29/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
TMB Submitted by Illumina Inc. on 05/13/2021
Cabazitaxel Submitted by Sanofi on 11/04/2021
Nivolumab + Ipilimumab Submitted by Bristol-Myers Squibb Company on 04/11/2022
Comprehensive Genomic Profiling + Circulating Tumor DNA (ctDNA) Assay Submitted by Guardant Health on 05/18/2022

Thyroid Carcinoma Panel

Thyrotropin alfa Submitted by Sanofi on 08/31/2018
Larotrectinib Submitted by Bayer HealthCare on 10/15/2018
Thyrotropin alfa Submitted by Sanofi on 04/22/2019
Entrectinib Submitted by Genentech, Inc. on 08/16/2019
Selpercatinib Submitted by Eli Lilly and Company on 05/08/2020
Pembrolizumab Submitted by Merck & Co., Inc. on 06/17/2020
Tumor Mutational Burden (TMB) Submitted by Foundation Medicine, Inc. on 06/29/2020
Pralsetinib Submitted by Blueprint Medicines on 12/01/2020
Cabozantinib Submitted by Exelixis Inc. on 09/21/2021
Lenvatinib and pembrolizumab Submitted by Eisai Inc. on 09/24/2021
Diagnostic Procedures Submitted by Myriad Genetic Laboratories, Inc. on 09/24/2021
Molecular Diagnostics Submitted by Veracyte, Inc. on 10/06/2021